Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             619 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 181 Aberrant Wnt signaling activation in human cancers: In vitro and in vivo models to facilitate Wnt targeted drug development Liu, G.
 2014
 50 S6 p. 60-
1 p.
 artikel
2 537 Absolute quantitation of MET using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue Cecchi, F.
 2014
 50 S6 p. 175-
1 p.
 artikel
3 Acknowledgement 2014
 50 S6 p. xii-
1 p.
 artikel
4 251 A combined in vitro and mathematical modelling approach for understanding the impact of an inhibitor of ATR on DNA damage and repair after ionising radiation Yates, J.
 2014
 50 S6 p. 84-
1 p.
 artikel
5 78 A comprehensive in vitro screen to identify therapeutic candidates for inclusion with etoposide/platin combinations to improve treatment of SCLC Evans, D.
 2014
 50 S6 p. 30-
1 p.
 artikel
6 83 Acquired resistance to BET bromodomain inhibitors is associated with modulation of the apoptotic signaling network Sandy, P.
 2014
 50 S6 p. 31-32
2 p.
 artikel
7 4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2 Taplin, M.E.
 2014
 50 S6 p. 8-
1 p.
 artikel
8 53 Adeno-associated virus (AAV) carrying diphtheria toxin a gene for pancreatic cancer therapy Chen, M.
 2014
 50 S6 p. 22-
1 p.
 artikel
9 135 AD-O64.3: IFN-γ–TRAIL fusion protein. Use of two independent signaling pathways for a strong synergistic antitumor effect Zerek, B.
 2014
 50 S6 p. 47-
1 p.
 artikel
10 519 AD-O53.2 – novel biological anticancer therapeutic agent with a dual mechanism of action Poleszak, K.
 2014
 50 S6 p. 169-
1 p.
 artikel
11 590 A dose dense schedule improves antitumor activity of trabectedin in myxoid liposarcoma with type III FUS-CHOP chimera Uboldi, S.
 2014
 50 S6 p. 190-
1 p.
 artikel
12 296 A first-in-Asian phase I dose escalation study to evaluate the safety and pharmacokinetics of VS-6063 (defactinib), a focal adhesion kinase inhibitor in subjects with non-hematologic malignancies Shimizu, T.
 2014
 50 S6 p. 97-98
2 p.
 artikel
13 378 A first-in-human (FIH) safety and pharmacological study of SAR405838, a novel HDM2 antagonist, in patients with solid malignancies de Weger, V.
 2014
 50 S6 p. 121-122
2 p.
 artikel
14 329 A first-in-human study evaluating the safety and pharmacology of MM-151, a novel oligoclonal anti-EGFR antibody combination in patients with refractory solid tumors Beeram, M.
 2014
 50 S6 p. 107-
1 p.
 artikel
15 291 Aflibercept has anti-tumor activity in bevacizumab-escaping tumors of colorectal cancer: Molecular profiles and mechanisms Dib, C.
 2014
 50 S6 p. 96-
1 p.
 artikel
16 406 Aflibercept (Zaltrap) directly attenuates the migration and invasion of colorectal cancer cells Bouygues, A.
 2014
 50 S6 p. 130-
1 p.
 artikel
17 3 Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer Blagden, S.
 2014
 50 S6 p. 7-
1 p.
 artikel
18 195 A humanized mouse model for preclinical testing of molecules targeting immune checkpoints Baia, G.
 2014
 50 S6 p. 63-
1 p.
 artikel
19 280 A hybrid drug design approach to overcome imatinib resistance for treating leukemia Wei, Y.M.
 2014
 50 S6 p. 93-
1 p.
 artikel
20 69 AKT3 activation mediates resistance to HER2-targeted therapies in HER2-amplified breast cancer Sanz, F. Carmona
 2014
 50 S6 p. 27-28
2 p.
 artikel
21 373 AKT2 gene amplification is a marker for sensitivity to allosteric but not ATP-competitive AKT inhibitors Abe, T.
 2014
 50 S6 p. 120-
1 p.
 artikel
22 16 Allografting improves the feasibility of genetically engineered mouse models (GEMM) for anti-cancer drug development Kukuk, K.
 2014
 50 S6 p. 11-12
2 p.
 artikel
23 355 Altiratinib (DCC-2701): a balanced inhibitor of MET, TIE2, and VEGFR2 kinases that exhibits broad anti-tumor and anti-angiogenic activities Flynn, D.
 2014
 50 S6 p. 115-
1 p.
 artikel
24 121 A modified double-deleted vaccinia virus combining viral oncolysis and potential gene therapy as a novel therapeutic for atypical teratoid/rhabdoid tumors Ruan, Y.
 2014
 50 S6 p. 42-43
2 p.
 artikel
25 507 Amplification of D-type cyclin genes CCND2 and CCND3 confers an oncogene addiction phenotype in tumor cells and hypersensitivity to the CDK4/6 inhibitor LY2835219 Buchanan, S.
 2014
 50 S6 p. 165-
1 p.
 artikel
26 525 Analysing Src and phosphoinositide 3-kinase pathway inhibition in a radiotherapy context – pathway interplay and therapeutic response Rowling, E.
 2014
 50 S6 p. 170-171
2 p.
 artikel
27 420 Analysis of genomic alterations in Ewing sarcoma (German cohort) reveals cooperating mutations and novel therapy targets Richter, G.H.S.
 2014
 50 S6 p. 134-
1 p.
 artikel
28 133 Analysis of immune microenvironment in resectable NSCLC: Prognostic value of regulatory and conventional T cell markers proportion Uso, M.
 2014
 50 S6 p. 46-
1 p.
 artikel
29 122 Analysis of immune-response markers in resectable NSCLC Usó, M.
 2014
 50 S6 p. 43-
1 p.
 artikel
30 233 Analytical validation and application of the MPACT assay, a next generation sequencing based targeted mutation detection assay for treatment selection Lih, C.
 2014
 50 S6 p. 78-
1 p.
 artikel
31 285 A nanomolar-potency small molecule inhibitor of the STAT5 protein Cumaraswamy, A.A.
 2014
 50 S6 p. 94-
1 p.
 artikel
32 308 Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway Gameiro, S.
 2014
 50 S6 p. 101-
1 p.
 artikel
33 24 Androgen receptor (AR) expression in triple negative breast cancer (TNBC): results from a phase II neoadjuvant trial with carboplatin and eribulin mesylate in TNBC patients Siziopikou, K.
 2014
 50 S6 p. 14-
1 p.
 artikel
34 272 8-(1-Anilino)ethyl)-2-morpholino-4-oxo-4H-chromene-6-carboxamides as PI3Kbeta/delta inhibitors: structure–activity relationships and identification of AZD8186, a clinical candidate for the treatment of PTEN deficient tumours Barlaam, B.
 2014
 50 S6 p. 90-91
2 p.
 artikel
35 25 An ING1b-derived peptide that inhibits cancer cell viability and promotes apoptosis Boyko, A.
 2014
 50 S6 p. 14-
1 p.
 artikel
36 147 An integrated approach for identifying E-cadherin synthetic lethality networks Bajrami, I.
 2014
 50 S6 p. 50-
1 p.
 artikel
37 388 An integrated molecular analysis of lung adenocarcinomas identifies potential therapeutic targets among TTF1-negative tumors Cardnell, R.J.
 2014
 50 S6 p. 124-125
2 p.
 artikel
38 132 A novel anti-PDL1 antibody-based bifunctional protein with enhanced immunological activity Wu, Y.
 2014
 50 S6 p. 46-
1 p.
 artikel
39 549 A novel cancer marker and potential therapeutic target Parri, M.P.
 2014
 50 S6 p. 178-
1 p.
 artikel
40 403 A novel dielectrophoretic microwell array system for detection and single cell analysis of circulating tumor cells from breast cancer patients Sawada, T.
 2014
 50 S6 p. 129-
1 p.
 artikel
41 326 A novel non-ligand competing anti-EGFR antibody for cancer treatment Wang, X.
 2014
 50 S6 p. 106-
1 p.
 artikel
42 112 A novel primary human tumor explant platform provides a preclinical translational link from tissue culture to the clinic Juan, G.
 2014
 50 S6 p. 40-
1 p.
 artikel
43 211 A novel synthetic lethal interaction between the histone mark H3K36me3 and checkpoint kinases Pfister, S.X.
 2014
 50 S6 p. 71-
1 p.
 artikel
44 171 Antagonistic interaction between gemcitabine and erlotinib is influenced by EGR1 (early growth response 1) transcription factor expression Hose, C.D.
 2014
 50 S6 p. 57-
1 p.
 artikel
45 556 Antagonizing microRNA mediated epigenetic reprogramming as therapeutic strategy for aggressive prostate cancer Dallavalle, C.
 2014
 50 S6 p. 180-
1 p.
 artikel
46 530 Anti-angiogenic therapy induces T-lymphocyte infiltration associated with poor survival in metastatic renal cell carcinoma patients Liu, X.D.
 2014
 50 S6 p. 172-
1 p.
 artikel
47 115 Anti-metastatic activity via co-blockade of PD-1 and adenosine A2A receptor Mittal, D.
 2014
 50 S6 p. 40-41
2 p.
 artikel
48 9 Antineoplastic effects of auranofin in canine lymphoma Thamm, D.
 2014
 50 S6 p. 9-10
2 p.
 artikel
49 523 Antitumor activity of mTOR kinase and DNA-PK inhibitor CC-115 in a mouse model of glioblastoma Raymon, H.
 2014
 50 S6 p. 170-
1 p.
 artikel
50 70 Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRa-expressing cells Pan, J.
 2014
 50 S6 p. 28-
1 p.
 artikel
51 62 Antitumor and temozolomide-sensitizing effects of sodium metaarsenite in an orthotopic glioblastoma xenograft model Kang, W.Y.
 2014
 50 S6 p. 25-
1 p.
 artikel
52 276 An X-ray crystal structure-based understanding of the inhibition of the MDM2–p53 protein–protein interaction by isoindolinones Anil, B.
 2014
 50 S6 p. 91-92
2 p.
 artikel
53 435 A pan-cancer tumor-derived epithelial-to–mesenchymal transition (EMT) signature determines patterns of drug sensitivity and enrichment in immune target expression following EMT Mak, M.P.
 2014
 50 S6 p. 143-
1 p.
 artikel
54 11 A panel of patient derived xenograft models of different haematological malignancies suitable for preclinical drug screening campaigns Oswald, E.
 2014
 50 S6 p. 10-
1 p.
 artikel
55 61 A panel of pediatric liver cancer patient-derived xenografts to improve stratification of children with hepatoblastoma Fabre, M.
 2014
 50 S6 p. 25-
1 p.
 artikel
56 389 A phase 1, dose-escalation, first-in-human study of ARQ 087, an oral pan-FGFR inhibitor, in adult subjects with advanced solid tumors Papadopoulos, K.
 2014
 50 S6 p. 125-
1 p.
 artikel
57 508 A phase Ib trial of AMG386 and temsirolimus in patients with advanced sold tumors (PJC-008/NCI#9041) Chiu, J.W.
 2014
 50 S6 p. 165-166
2 p.
 artikel
58 213 A phase I dose-finding study of BI 853520, a potent and selective inhibitor of focal adhesion kinase (FAK), in Japanese and Taiwanese patients with advanced or metastatic solid tumors Doi, T.
 2014
 50 S6 p. 72-
1 p.
 artikel
59 526 A Phase I study of the dual, intravenous (IV) phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 in combination with irinotecan in patients (pts) with colorectal cancer (CRC) and other advanced solid tumors Wainberg, Z.
 2014
 50 S6 p. 171-
1 p.
 artikel
60 461 A phase I trial of dabrafenib (BRAF inhibitor) and pazopanib in BRAF mutated advanced malignancies Haraldsdottir, S.
 2014
 50 S6 p. 151-
1 p.
 artikel
61 342 A phase 1/2 study evaluating the safety, pharmacokinetics and efficacy of ABT-414 in subjects with advanced solid tumors likely to over-express the epidermal growth factor receptor (EGFR) Tolcher, A.
 2014
 50 S6 p. 111-
1 p.
 artikel
62 210 A phase 1 study of KTN3379, a human anti-ErbB3 monoclonal antibody in patients with advanced cancers LoRusso, P.
 2014
 50 S6 p. 71-
1 p.
 artikel
63 105 A platform to test multiple therapy options simultaneously in a patient's own tumor Caffo, N.
 2014
 50 S6 p. 38-
1 p.
 artikel
64 334 Aplidin: first in class compound targeting EEF1A in tumor cells Losada, A.
 2014
 50 S6 p. 108-
1 p.
 artikel
65 268 A potent and highly efficacious bivalent Smac Mimetic APG-1387 in Phase I clinical development Lu, J.
 2014
 50 S6 p. 89-
1 p.
 artikel
66 408 A potent and selective small molecule inhibitor of MCL-1 sensitizes DLBCL cell lines to the BCL-2 selective inhibitor ABT-199 Phillips, D.C.
 2014
 50 S6 p. 130-
1 p.
 artikel
67 528 A procaspase activator shows preclinical promise for glioblastoma therapy Riggins, G.
 2014
 50 S6 p. 171-172
2 p.
 artikel
68 557 A rational approach for discovery of inhibitors of YAP-TEAD interaction Chene, L.
 2014
 50 S6 p. 180-
1 p.
 artikel
69 117 “Arming” the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumours Champion, B.
 2014
 50 S6 p. 41-
1 p.
 artikel
70 145 ARQ 087, a novel pan FGFR-inhibitor crosses the BBB (blood–brain barrier) and distributes to the brain of rats Savage, R.
 2014
 50 S6 p. 50-
1 p.
 artikel
71 144 Association between interleukin 17/interleukin 17 receptor gene polymorphism and papillary thyroid cancer Eun, Y.
 2014
 50 S6 p. 50-
1 p.
 artikel
72 93 A stress induced early innate response causes multi-drug tolerance in melanoma Menon, D.R.
 2014
 50 S6 p. 34-
1 p.
 artikel
73 164 Augmentation of NAD+ by NQO1 activation attenuates cisplatin-mediated hearing impairment Yang, S.
 2014
 50 S6 p. 55-
1 p.
 artikel
74 405 Aurora kinases A and B are required for KRAS-induced lung cell oncogenicity Santos, E.O. Ozorio dos
 2014
 50 S6 p. 129-130
2 p.
 artikel
75 Author Index 2014
 50 S6 p. 205-228
24 p.
 artikel
76 266 Auxiliar treatment by targeting the extracellular matrix to improve drug delivery and therapeutic response Henke, E.
 2014
 50 S6 p. 89-
1 p.
 artikel
77 124 A WT1-derived peptide protects against metastatic melanoma in a syngeneic model by in vivo immunomodulatory effects on dendritic cells Massaoka, M.H.
 2014
 50 S6 p. 43-44
2 p.
 artikel
78 156 Behaviour of platinum(IV) complexes with prodrug function in different models of hypoxia Brynzak, E.
 2014
 50 S6 p. 53-
1 p.
 artikel
79 106 Beta-3 integrin inhibition reduces inflammatory cytokine release but not anti-cancer activity of oncolytic adenovirus in ovarian cancer Browne, A.K.
 2014
 50 S6 p. 38-
1 p.
 artikel
80 315 Biological characterization of TAS3681, a new type of androgen receptor antagonist with androgen receptor downregulating activity Minamiguchi, K.
 2014
 50 S6 p. 103-
1 p.
 artikel
81 569 Biological consequences of selective inhibition of the first BET bromodomain Seitzberg, J.G.
 2014
 50 S6 p. 184-
1 p.
 artikel
82 465 Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC) Kapoun, A.
 2014
 50 S6 p. 152-
1 p.
 artikel
83 331 Biomarker discovery and validation for assessing the response to cMet inhibition and functional inactivation Jung, S.
 2014
 50 S6 p. 107-
1 p.
 artikel
84 434 Bipolar androgen therapy for men with castration sensitive and castration resistant prostate cancer: Reversing resistance and maintaining sensitivity to androgen ablative therapies Denmeade, S.R.
 2014
 50 S6 p. 143-
1 p.
 artikel
85 338 BM-1252 (APG-1252): a potent dual specific Bcl-2/Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity Bai, L.
 2014
 50 S6 p. 109-110
2 p.
 artikel
86 242 BMN 673 as single agent and in combination with temozolomide or PI3K pathway inhibitors in small cell lung cancer and gastric cancer models Feng, Y.
 2014
 50 S6 p. 81-
1 p.
 artikel
87 169 BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform (Idylla™) Janku, F.
 2014
 50 S6 p. 56-57
2 p.
 artikel
88 35 BRCA1 expression exploratory analysis in patients of the phase III trial of trabectedin vs. doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas Aracil, M.
 2014
 50 S6 p. 17-
1 p.
 artikel
89 46 Broad-spectrum preclinical combination activity of eribulin combined with various anticancer agents in human breast cancer, lung cancer, ovarian cancer, and melanoma xenograft models Asano, M.
 2014
 50 S6 p. 20-
1 p.
 artikel
90 119 3-Bromopyruvate as an inducer of immunogenic cell death in colon cancer cells Jung, K.H.
 2014
 50 S6 p. 42-
1 p.
 artikel
91 347 Can a link between the EGFR and cMET pathway in non-small cell lung cancer explain resistance against targeted therapies and open new therapeutic opportunities? van der Steen, N.
 2014
 50 S6 p. 112-
1 p.
 artikel
92 68 Can the P53 status predict the outcome of Polo-like kinase 1 inhibition in non-small cell lung cancer cell lines? Van den Bossche, J.
 2014
 50 S6 p. 27-
1 p.
 artikel
93 555 CB-5083, a first in class inhibitor of the AAA-ATPase p97/VCP, induces irresolvable ER stress that results in antitumor activity in solid and hematological tumor models Yakes, F.
 2014
 50 S6 p. 180-
1 p.
 artikel
94 422 CBL0137, a novel NFkB suppressor and p53 activator, is highly effective in pre-clinical models of neuroblastoma Haber, M.
 2014
 50 S6 p. 135-
1 p.
 artikel
95 306 CC-115 inhibits DNA damage and repair pathways in vitro Tsuji, T.
 2014
 50 S6 p. 100-
1 p.
 artikel
96 168 CDCP1 as a new marker of aggressiveness in triple-negative breast cancers Campiglio, M.
 2014
 50 S6 p. 56-
1 p.
 artikel
97 498 CDK4/6 inhibitor (LY2835219) exhibits potent anti-tumor activity in human lung cancer cell lines with intact retinoblastoma Goldman, J.W.
 2014
 50 S6 p. 162-
1 p.
 artikel
98 43 CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors Hung, L.
 2014
 50 S6 p. 19-20
2 p.
 artikel
99 108 CD70 (TNFSF7), a receptor involved in acute immune modulation of viral infection, is frequently overexpressed in solid and hematological malignancies Jacobs, J.
 2014
 50 S6 p. 39-
1 p.
 artikel
100 587 Cellular pharmacokinetics and molecular pharmacodynamics studies of the BRD-BET inhibitor OTX015 in sensitive and resistant leukemic cell lines Odore, E.
 2014
 50 S6 p. 189-
1 p.
 artikel
101 397 Characterization of molecular targets of therapy in Non-Small Cell Lung Cancer (NSCLC) utilizing a liquid biopsy Greene, S.
 2014
 50 S6 p. 127-
1 p.
 artikel
102 129 Characterization of PD-L1 expression in circulating tumor cells (CTCs) of non-small cell lung cancer (NSCLC) patients Krupa, R.
 2014
 50 S6 p. 45-
1 p.
 artikel
103 577 Characterization of the cellular mechanism of action of the first in class investigational inhibitor of the Ubiquitin Activating Enzyme, MLN7243 Milhollen, M.
 2014
 50 S6 p. 186-
1 p.
 artikel
104 402 Characterization of the oncogenic properties of mutant isocitrate dehydrogenase 1 (IDH1R132H) in human primary cells Barradas, M.
 2014
 50 S6 p. 128-129
2 p.
 artikel
105 28 Characterization of the type of cell death induced by novel tambjamine analogs in lung cancer Martín, A. Rodilla
 2014
 50 S6 p. 15-
1 p.
 artikel
106 245 Chk1 is a potential novel therapeutic target that regulates cell survival and potentiates chemotherapy in osteosarcoma (OS) models Strauss, S.J.
 2014
 50 S6 p. 82-
1 p.
 artikel
107 107 CIGB-247: Anti-VEGF therapeutic vaccine in patients with advanced solid tumors Hernández-Bernal, F.
 2014
 50 S6 p. 38-
1 p.
 artikel
108 428 Clinical acquired resistance to combined RAF/EGFR or RAF/MEK inhibition in BRAF mutant colorectal cancer (CRC) patients through MAPK pathway alterations Corcoran, R.
 2014
 50 S6 p. 141-
1 p.
 artikel
109 41 Clinical activity of BIND-014 (docetaxel nanoparticles for injectable suspension) as second-line therapy in patients (pts) with Stage III/IV non-small cell lung cancer Natale, R.
 2014
 50 S6 p. 19-
1 p.
 artikel
110 231 Clinical pharmacodynamic assay development for the first in class investigational ubiquitin activating enzyme (UAE) inhibitor MLN7243 Bahamón, B.
 2014
 50 S6 p. 78-
1 p.
 artikel
111 324 Clinical pharmacokinetics (PK), translational PK/pharmacodynamics (PD), and exposure–adverse events (AEs) relationship of MLN2480, an oral investigational pan-RAF kinase inhibitor Zhou, X.
 2014
 50 S6 p. 105-106
2 p.
 artikel
112 462 Clinical sequencing of cancer in real-time by digital sequencing of cell-free DNA for tailoring targeted therapy in refractory cancer patients Talasaz, A.
 2014
 50 S6 p. 151-
1 p.
 artikel
113 66 Clinical validity of new genetic biomarkers of irinotecan neutropenia: An independent replication study Innocenti, F.
 2014
 50 S6 p. 26-27
2 p.
 artikel
114 468 Clinicopathologic implication of c-MYC gene copy number gain and overexpression in colorectal cancer Lee, K.
 2014
 50 S6 p. 153-
1 p.
 artikel
115 CME Accreditation 2014
 50 S6 p. xvii-
1 p.
 artikel
116 395 cMet: Proof-of-concept clinical trial with volitinib in patients with advanced papillary renal cell cancer (PRCC) Choueiri, T.K.
 2014
 50 S6 p. 126-127
2 p.
 artikel
117 458 Combinational genome and proteome survey of therapeutic targets of hepatocellular carcinoma Yamada, T.
 2014
 50 S6 p. 150-
1 p.
 artikel
118 327 Combination of MDM2 antagonists with RAS pathway inhibitors in colorectal cancer Higgins, B.
 2014
 50 S6 p. 106-
1 p.
 artikel
119 174 Combination of molecular and drug response data in patient-derived xenografts to assist patient stratification Cairo, S.
 2014
 50 S6 p. 58-
1 p.
 artikel
120 387 Combination of the ERK inhibitor GDC-0994 with the MEK inhibitor cobimetinib significantly enhances anti-tumor activity in KRAS and BRAF mutant tumor models Merchant, M.
 2014
 50 S6 p. 124-
1 p.
 artikel
121 99 Combination screening of investigational oncology agents Holbeck, S.
 2014
 50 S6 p. 36-
1 p.
 artikel
122 208 Combined treatment of a DNA-PKcs inhibitor (NU7441) and ionizing radiation causes a differential mode of cell death in a panel of NSCLC cell lines and exhibits robust radiosensitisation Saha, D.
 2014
 50 S6 p. 68-
1 p.
 artikel
123 295 Combining forces: Study of the cytotoxic effect of the MDM2 inhibitor Nutlin-3 in combination with CDDP in non-small cell lung cancer cell lines Deben, C.
 2014
 50 S6 p. 97-
1 p.
 artikel
124 33 Combining the long-acting topoisomerase 1-inhibitor etirinotecan pegol with the PARP inhibitor rucaparib to provide anti-tumor synergy without increased toxicity Hoch, U.
 2014
 50 S6 p. 16-17
2 p.
 artikel
125 511 ComboPredictor: identification of synergy biomarkers and enrichment within tumor sample populations Tomilo, M.
 2014
 50 S6 p. 166-
1 p.
 artikel
126 102 Comparison of platinum/taxane and anthracycline-based therapies in ovarian PDX models: Correlating stage of biopsy collection and engrafting with in vivo drug sensitivity Meade, J.
 2014
 50 S6 p. 37-
1 p.
 artikel
127 250 Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes Chmielecki, J.
 2014
 50 S6 p. 84-
1 p.
 artikel
128 415 Comprehensive next generation sequencing of solid tumors from 669 adolescents and young adults reveals a distinct spectrum of targetable genomic alterations Morosini, D.
 2014
 50 S6 p. 132-133
2 p.
 artikel
129 Conference Committees 2014
 50 S6 p. xi-
1 p.
 artikel
130 263 Controlled release of cisplatin using hyaluronic oligosaccharides-coated gold nanoparticles as an efficient delivery system applied to the treatment of pancreatic tumors Parkkola, H.
 2014
 50 S6 p. 87-88
2 p.
 artikel
131 127 Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population Garon, E.G.
 2014
 50 S6 p. 44-45
2 p.
 artikel
132 359 Correlation of tumour-associated macrophage, but not tumour-infiltrating lymphocyte, levels with progression-free survival in patients with metastatic renal cell carcinoma treated with axitinib Williams, J.A.
 2014
 50 S6 p. 116-
1 p.
 artikel
133 451 Correlative and updated clinical endpoint analysis of a multicenter phase II trial of selumetinib (AZD6244) plus erlotinib in chemotherapy-refractory advanced pancreatic adenocarcinoma (PDAC) Ko, A.H.
 2014
 50 S6 p. 148-
1 p.
 artikel
134 87 Critical difference in development of acquired resistance to MDM2 inhibitor SAR405838 in vitro and in vivo Hoffman-Luca, G.
 2014
 50 S6 p. 32-33
2 p.
 artikel
135 125 Critical issues in the clinical development of oncolytic viruses – A regulatory perspective Schuessler-Lenz, M.
 2014
 50 S6 p. 44-
1 p.
 artikel
136 449 Cytokine induces MIR-424 expression and modulates SOCS2/STAT5 signaling pathway in oral cancer Shiah, S.G.
 2014
 50 S6 p. 147-
1 p.
 artikel
137 363 Cytosolic p21 is a pharmacodynamic marker of CHEK1 and IKK inhibition in ovarian cancer cells Kim, M.
 2014
 50 S6 p. 117-
1 p.
 artikel
138 67 Cytotoxic response as a result of the cross-talk between UGT mediated metabolism and modulation of UGT activity by C-1311 and C-1305 acridinone antitumor agents in selected solid tumor cell lines Mazerska, Z.
 2014
 50 S6 p. 27-
1 p.
 artikel
139 271 Data integration and graph analysis for cancer genomics and drug discovery Bernard, B.
 2014
 50 S6 p. 90-
1 p.
 artikel
140 444 Debio 1143 in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and platinum-refractory epithelial ovarian cancer (EOC). Preliminary results of a Phase I dose-escalation study Le Tourneau, C.
 2014
 50 S6 p. 146-
1 p.
 artikel
141 120 Density of CD 8 +ve T cells & CD 56 +ve NK cells in follicular adenoma & papillary carcinoma of thyroid in Pakistani population Varda, J.
 2014
 50 S6 p. 42-
1 p.
 artikel
142 430 Design and structure–activity relationships of highly potent and bioavailable imidazolinone FASN KR domain inhibitors Bignan, G.
 2014
 50 S6 p. 141-142
2 p.
 artikel
143 509 Detecting gene amplification in circulating tumor cells of patients with gastric cancer for clinical trial Mishima, Y.
 2014
 50 S6 p. 166-
1 p.
 artikel
144 533 Detection of recurrent novel fusion transcripts from whole transcriptome sequencing of 120 primary breast cancer Kim, J.
 2014
 50 S6 p. 173-
1 p.
 artikel
145 80 Determination of an oxidative stress gene signature in inflammatory breast cancer patient tumors and development of a novel redox modulatory strategy in overcoming chemotherapy resistance and mediating anti-tumor efficacy Devi, G.R.
 2014
 50 S6 p. 31-
1 p.
 artikel
146 491 Development and characteristics of resistance to the HER family tyrosine kinase inhibitor AZD8931 Brunton, V.G.
 2014
 50 S6 p. 160-
1 p.
 artikel
147 489 Development and clinical validation of a quantitative mass spectrometric assay for PD-L1 protein in FFPE NSCLC samples An, E.
 2014
 50 S6 p. 159-
1 p.
 artikel
148 538 Development of a novel anti-tumor antibody targeting CXADR Kawada, M.
 2014
 50 S6 p. 175-
1 p.
 artikel
149 313 Development of a one-step isolation platform for exosomal RNA and circulating cell-free DNA from cancer plasma samples Enderle, D.
 2014
 50 S6 p. 102-
1 p.
 artikel
150 488 Development of a publicly accessible knowledgebase to facilitate decision support for clinical cancer genomics reporting Shaw, K.
 2014
 50 S6 p. 159-
1 p.
 artikel
151 548 Development of a small molecule activator of protein phosphatase 2A for the treatment of prostate cancer McClinch, K.
 2014
 50 S6 p. 178-
1 p.
 artikel
152 232 Development of a targeted NGS assay system for patient enrollment to the NCI-MATCH study Williams, M.
 2014
 50 S6 p. 78-
1 p.
 artikel
153 559 Development of a unique biologic for treating cysteine-dependent malignancies Stone, E.
 2014
 50 S6 p. 181-
1 p.
 artikel
154 429 Development of extracellular signal-regulated kinase 5 (ERK5) inhibitors for anti-cancer therapy Myers, S.
 2014
 50 S6 p. 141-
1 p.
 artikel
155 257 Development of peptide-mediated drug delivery systems for colon cancer targeted imaging and therapy Wu, H.C.
 2014
 50 S6 p. 86-
1 p.
 artikel
156 51 Development of rational combination therapy strategies to optimize treatment for GPNMB expressing Her2+ and triple negative breast cancer Rose, A.
 2014
 50 S6 p. 22-
1 p.
 artikel
157 486 Development of small molecule activators of protein phosphatase 2A for the treatment of lung cancer Sangodkar, J.
 2014
 50 S6 p. 158-159
2 p.
 artikel
158 244 Development of xenoimplants from germline BRCA1/2 mutant breast cancer (BC) for the identification of predictive biomarkers, mechanisms of resistance against poly(ADP-ribose) polymerase (PARP) inhibitors and evaluation of novel therapies Cruz, C.
 2014
 50 S6 p. 82-
1 p.
 artikel
159 369 Diagnosis and molecular targeting for individualized treatment of patients with pre-neoplastic lesions and locally advanced cervical cancer Moreno-Acosta, P.M.A.
 2014
 50 S6 p. 119-
1 p.
 artikel
160 516 Different genetic profiles of resistant and sensitive patients with EGFR wild type NSCLC undergoing tyrosine kinase inhibitor (TKI) treatment Ulivi, P.U.
 2014
 50 S6 p. 168-
1 p.
 artikel
161 57 Differential antitumor activity of trabectedin, lurbinectedin, Zalypsis and PM00128 against a panel of human cells deficient in transcription and NER factors Moneo, V.
 2014
 50 S6 p. 24-
1 p.
 artikel
162 190 Differential chemosensitivity between CETCs and tumour spheroids in cancer patients with solid tumors Zimon, D.
 2014
 50 S6 p. 62-
1 p.
 artikel
163 73 Differential pathway resiliency in response to MAPK inhibition in BRAF-mutant cancer Sos, M.
 2014
 50 S6 p. 28-29
2 p.
 artikel
164 341 Dinaciclib alters cell cycle dynamics and induces cell death in Soft Tissue Sarcomas Margalef, N. Mulet
 2014
 50 S6 p. 110-
1 p.
 artikel
165 270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors Tognolini, M.
 2014
 50 S6 p. 90-
1 p.
 artikel
166 552 Discovery of an unexpected vulnerability of cancer stem-like cells via a functional dissection of EMT biology Feng, Y.
 2014
 50 S6 p. 179-
1 p.
 artikel
167 279 Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agent Hsieh, H.P.
 2014
 50 S6 p. 92-93
2 p.
 artikel
168 59 Discovery of novel inhibitor of FOXO nuclear–cytoplasmic shuttling from natural products of marine origin Correa, F.J. Castillo
 2014
 50 S6 p. 24-
1 p.
 artikel
169 356 Discovery of novel pyrido[2,3-b]pyrazine as fibroblast growth factor receptor (FGFR-1, 2, 3 & 4) kinase inhibitors with nanomolar affinity Angibaud, P.
 2014
 50 S6 p. 115-
1 p.
 artikel
170 370 Discovery of the genes that underpin the transition to malignant phenotype of breast tissues in a highly consanguineous region Gupta, I.
 2014
 50 S6 p. 119-
1 p.
 artikel
171 495 Divergent androgen regulation of UPR pathways drives prostate cancer Arnoldussen, Y.J.
 2014
 50 S6 p. 161-
1 p.
 artikel
172 229 DNA methyltransferase 1 expression in human solid tumors and lymphomas by immunohistochemistry Yang, S.X.
 2014
 50 S6 p. 77-
1 p.
 artikel
173 221 Docosahexaenoic acid along with modulation of actin binding proteins reduces cancer cell migration Ali, M.
 2014
 50 S6 p. 75-
1 p.
 artikel
174 472 Do we hit the target? Phospho-reactome measurements determine efficacy of targeted therapies van't Veer, L.
 2014
 50 S6 p. 154-
1 p.
 artikel
175 162 Drug–drug interaction predictions for MLN2480, an investigational pan-RAF inhibitor, based on nonclinical data Balani, S.K.
 2014
 50 S6 p. 54-55
2 p.
 artikel
176 411 Druggability of p16 deleted pediatric leukemia: The novel cell line POETIC3 identifies potential agents and drug combinations for mechanism based targeted therapeutics Reimer, J.
 2014
 50 S6 p. 131-
1 p.
 artikel
177 154 Drug response database with PDX tumor models in biomarker-driven multi-drug multi-arm clinical trial settings Jiang, J.
 2014
 50 S6 p. 52-
1 p.
 artikel
178 554 Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells Brown, R.
 2014
 50 S6 p. 179-180
2 p.
 artikel
179 332 Dual PI3K delta/gamma inhibition by RP6530 accentuates bortezomib activity in multiple myeloma cell lines Viswanadha, S.
 2014
 50 S6 p. 108-
1 p.
 artikel
180 45 Early preclinical study of BO-2094 for treatment of human colon cancer, in combination with 5-fluorouracil Su, T.L.
 2014
 50 S6 p. 20-
1 p.
 artikel
181 91 4E-BP1 expression levels determine sensitivity of triple negative breast cancer cells to mTOR inhibitors Jastrzebski, K.
 2014
 50 S6 p. 34-
1 p.
 artikel
182 487 EC-70124, a multi-kinase inhibitor, blocks NF-kB and STAT3 dependent signaling in prostate cancer stem cells Civenni, G.
 2014
 50 S6 p. 159-
1 p.
 artikel
183 Editorial Board 2014
 50 S6 p. ii-
1 p.
 artikel
184 37 Effect of a microtubule-targeting drug on cell–cell contacts in bladder epithelial tumour cells Antón-Aparicio, L.M.
 2014
 50 S6 p. 17-18
2 p.
 artikel
185 165 Effect of zoledronic acid on the post-translational modification of activated leukocyte cell adhesion molecule (ALCAM) in cancer cells Toth, R.
 2014
 50 S6 p. 55-
1 p.
 artikel
186 179 Effects of human breast cancer cells secreted factors on macrophage differentiation de Sousa, S. Coimbra
 2014
 50 S6 p. 59-
1 p.
 artikel
187 226 Efficacy of cancer preventing drugs administered by intermittent dosing regimens Steele, V.E.
 2014
 50 S6 p. 76-
1 p.
 artikel
188 381 Efficacy of specific FGFR inhibitors against gatekeeper resistance mutations and shared mechanism of cell death in FGFR2-dependent endometrial cancer cell lines Packer, L.
 2014
 50 S6 p. 122-
1 p.
 artikel
189 452 eIF2alpha phosphorylation determines the adaptation of tuberous sclerosis complex mutant cells to stress and their response to anti-tumor therapies Koromilas, A.
 2014
 50 S6 p. 148-
1 p.
 artikel
190 94 Elucidating mechanisms of resistance to FGFR inhibitors in endometrial cancer Packer, L.
 2014
 50 S6 p. 35-
1 p.
 artikel
191 579 Eph/ephrin-B interactions modulate a BAFF-R/TACI dependent survival of chronic lymphocytic leukemia (CLL) cells mediated in vitro by bone marrow stromal cells Alonso-Colmenar, L.M.
 2014
 50 S6 p. 187-
1 p.
 artikel
192 134 Epigenetic immunomodulation by SGI-110 combined with immune checkpoint blockade for new therapeutic strategies Covre, A.
 2014
 50 S6 p. 47-
1 p.
 artikel
193 241 Epigenetic loss-of-function BRCA1 mediates tumor cure by single dose radiotherapy Campagne, C.
 2014
 50 S6 p. 81-
1 p.
 artikel
194 18 Establishment and characterization of a Merkel Cell carcinoma PDX panel: Screening for potentially useful therapies Wick, M.J.
 2014
 50 S6 p. 12-
1 p.
 artikel
195 178 Establishment of patient-derived xenografts (PDX) models for small cell lung (SCL) as a pre-clinical platform for drug development Broudy, T.
 2014
 50 S6 p. 59-
1 p.
 artikel
196 146 Establishment of patient-derived xenografts (PDX) models for triple negative breast cancer (TNBC) as a pre-clinical platform for drug development Thatte, J.
 2014
 50 S6 p. 50-
1 p.
 artikel
197 222 Estimating predictive values of short-term morphologic assays of cancer chemoprevention for efficacy in animal tumor assays Dunn, B.
 2014
 50 S6 p. 75-
1 p.
 artikel
198 417 Evaluating the activity of the p53-MDM2 inhibitor NDD0005 in Ewing sarcoma Pecqueur, J.
 2014
 50 S6 p. 133-
1 p.
 artikel
199 532 Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial Glas, A.
 2014
 50 S6 p. 173-
1 p.
 artikel
200 425 Evaluation of drug reactions to anti-neoplastic agents in Phase I clinical trials Bupathi, M.
 2014
 50 S6 p. 136-
1 p.
 artikel
201 96 Evaluation of hormone therapies in a panel of breast PDX models: Relevance of ER status on sensitivity to letrozole and tamoxifen Wick, M.J.
 2014
 50 S6 p. 35-
1 p.
 artikel
202 522 Evaluation of the efficacy of melatonin in breast cancer metastasis mediated by ROCK-1 Borin, T.
 2014
 50 S6 p. 169-170
2 p.
 artikel
203 580 Evaluation of the pan-BET-bromodomain inhibitor OTX015 as a single agent and in combination with everolimus (RAD001) in triple-negative breast cancer models Vázquez, R.
 2014
 50 S6 p. 187-
1 p.
 artikel
204 290 Exosome analysis in cancer patients: From the preclinical towards the clinical application: Trial design Mertens, I.
 2014
 50 S6 p. 96-
1 p.
 artikel
205 448 Exposure to EGFR inhibitors influences release of extracellular vesicles by tumor cells van der Meel, R.
 2014
 50 S6 p. 147-
1 p.
 artikel
206 534 Expression of c-MET in invasive meningioma Yun, S.
 2014
 50 S6 p. 174-
1 p.
 artikel
207 192 Extensive characterization of patient derived colon cancer xenografts for preclinical biomarker identification Vuaroqueaux, V.
 2014
 50 S6 p. 62-63
2 p.
 artikel
208 259 Factors that limit delivery of Cdk4/6 inhibitor palbociclib to GBM Parrish, K.
 2014
 50 S6 p. 86-
1 p.
 artikel
209 302 FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells which are enriched by standard of care chemotherapy Pachter, J.
 2014
 50 S6 p. 99-
1 p.
 artikel
210 473 FDG PET/CT as imaging biomarker in the era of molecular targeting therapies: sequential FDG PET/CT demonstrated biological response and acquisition of resistance to tyrosine kinase inhibitor therapy for renal cell carcinoma Nakaigawa, N.
 2014
 50 S6 p. 154-
1 p.
 artikel
211 1 Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trials Meric-Bernstam, F.
 2014
 50 S6 p. 3-
1 p.
 artikel
212 476 FGFR2 targeting with allosteric inhibitor RPT835 Tsimafeyeu, I.
 2014
 50 S6 p. 155-
1 p.
 artikel
213 364 First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma Middleton, M.
 2014
 50 S6 p. 117-
1 p.
 artikel
214 320 First-in-human study with ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma Saleh, M.
 2014
 50 S6 p. 104-
1 p.
 artikel
215 504 Frequent loss-of-function mutations in MLK4 suppresses signaling in the JNK-cJUN-p21/p15 pathway to promote growth of colon cancer cells Marusiak, A.
 2014
 50 S6 p. 164-
1 p.
 artikel
216 109 Functional activity, but not PD-1 expression level, differentiates primary CLL from healthy PD1+ T cells using SCNP Liang, S.
 2014
 50 S6 p. 39-
1 p.
 artikel
217 175 Functional analysis of [methyl-3H]choline uptake in glioblastoma cells: Influence of anti-cancer and central nervous system drugs Inazu, M.
 2014
 50 S6 p. 58-
1 p.
 artikel
218 396 Gastrointestinal stromal tumor associated with neurofibromatosis type I Takahashi, T.
 2014
 50 S6 p. 127-
1 p.
 artikel
219 139 GBR1302: a BEAT® bispecific antibody for the treatment of HER2 positive cancers Croset, A.
 2014
 50 S6 p. 48-
1 p.
 artikel
220 General Information 2014
 50 S6 p. xiii-xvi
nvt p.
 artikel
221 15 Genetic and molecular validation of uterine sarcoma patient-derived xenograft models Cuppens, T.
 2014
 50 S6 p. 11-
1 p.
 artikel
222 198 Genetic and pharmacological inhibition of PIM-1 reduces tumor development in a K-Ras-driven mouse model of non-small cell lung cancer Aguirre, E.
 2014
 50 S6 p. 64-
1 p.
 artikel
223 297 Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC Chen, J.
 2014
 50 S6 p. 98-
1 p.
 artikel
224 88 Genome-wide drug sensitivity screens in haploid mouse embryonic stem cells Pettitt, S.J.
 2014
 50 S6 p. 33-
1 p.
 artikel
225 218 Genomic analysis identifies novel drivers and targetable pathways in inflammatory breast cancer patient samples Moran, D.M.
 2014
 50 S6 p. 74-
1 p.
 artikel
226 303 Genomic and epigenomic analysis identify potential therapeutic targets in luminal B breast cancer molecular subtype Klouche, L. Addou
 2014
 50 S6 p. 99-
1 p.
 artikel
227 167 Genomic characterisation of 1003 cancer cell-lines Bignall, G.
 2014
 50 S6 p. 56-
1 p.
 artikel
228 433 Genomic predictors of therapeutic sensitivity to TAS-119, a selective inhibitor of Aurora-A kinase Sootome, H.
 2014
 50 S6 p. 142-143
2 p.
 artikel
229 319 Genomic profiling of uterine leiomyosarcomas reveal frequent alterations in Akt/mammalian target of rapamycin (mTOR) pathway genes and other actionable genomic abnormalities linked to targeted therapies Elvin, J.A.
 2014
 50 S6 p. 104-
1 p.
 artikel
230 414 Genomic profiling using a clinical next generation sequencing (NGS) assay reveals genomic alterations to guide targeted therapy in advanced neuroblastoma patients Ali, S.
 2014
 50 S6 p. 132-
1 p.
 artikel
231 485 Glutathione S-transferases M1–5 reduce the aggressive behaviour in breast cancer by modulating the PI3K/AKT pathway Bergamaschi, A.
 2014
 50 S6 p. 158-
1 p.
 artikel
232 566 GNS396 and analogues are potent new small molecules to target and kill chemotherapy-resistant subpopulation cells in acute myeloid leukemia Bassissi, F.
 2014
 50 S6 p. 183-
1 p.
 artikel
233 427 Hematotoxicity potential of new drug candidates measured in hematopoietic progenitors in bone marrow samples Ballesteros, J.
 2014
 50 S6 p. 136-137
2 p.
 artikel
234 228 Her2–3 heterodimer is a new and better than HER2 IHC score for clinical outcome prognosis Weitsman, G.
 2014
 50 S6 p. 77-
1 p.
 artikel
235 230 High correlation between clinical responses to first line AML patients treated with cytarabine and idarubicin and their pharmacological profiles in patient samples measured by ExviTech Ballesteros, J.
 2014
 50 S6 p. 77-78
2 p.
 artikel
236 204 High-throughput functional screening identifies the flavoreductase POR as a principal determinant of sensitivity to the hypoxia-targeting prodrug SN30000 Hunter, F.W.
 2014
 50 S6 p. 66-
1 p.
 artikel
237 214 Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancer Haluska, P.
 2014
 50 S6 p. 72-73
2 p.
 artikel
238 191 Homotypic and heterotypic cell signaling transduction using a dielectrophoresis microfluidic device Gabriel, M. Tellez
 2014
 50 S6 p. 62-
1 p.
 artikel
239 260 Hsp90 Inhibitor Drug Conjugates (HDC): Payloads and possibilities Chimmanamada, D.
 2014
 50 S6 p. 87-
1 p.
 artikel
240 563 Hsp90 pharmacoproteomics: Harnessing pleiotropy for therapeutic synergy Goldstein, R.
 2014
 50 S6 p. 182-
1 p.
 artikel
241 514 Hypoxia inducible factor (HIF)-1a expression levels and p53 mutations are prognostic factors for survival in breast cancer patients treated with neoadjuvant chemotherapy Molina-Vila, M.
 2014
 50 S6 p. 167-
1 p.
 artikel
242 351 hz515H7, a humanized antibody exerts its antitumor activity via antagonism of the CXCR4/SDF-1 axis, and through effector functions Klinguer-Hamour, C.
 2014
 50 S6 p. 113-
1 p.
 artikel
243 325 Identification and characterization of an irreversible inhibitor of CDK2 Martin, M.
 2014
 50 S6 p. 106-
1 p.
 artikel
244 517 Identification and characterization of selective MELK kinase inhibitors Carpinelli, P.
 2014
 50 S6 p. 168-
1 p.
 artikel
245 379 Identification and rational in silico-based targeting of a novel mediator of metastatic breast cancer Clarkson, R.
 2014
 50 S6 p. 122-
1 p.
 artikel
246 160 Identification of fusion genes through kinome-centered RNA sequencing in different types of solid tumors Mittempergher, L.
 2014
 50 S6 p. 54-
1 p.
 artikel
247 581 Identification of genomic and chromatin features that predict transcriptional response to BET bromodomain inhibition Mertz, J.
 2014
 50 S6 p. 187-188
2 p.
 artikel
248 104 Identification of inhibitors of tryptophan metabolizing enzymes for cancer immunotherapy by high-throughput screening Zaman, G.
 2014
 50 S6 p. 37-38
2 p.
 artikel
249 594 Identification of novel EZH2 inhibitor scaffolds Espanel, X.
 2014
 50 S6 p. 191-
1 p.
 artikel
250 480 Identification of novel small molecules as selective PAK4 allosteric modulators (PAMs) by stable isotope labeling of amino acids in cells (SILAC) Senapedis, W.
 2014
 50 S6 p. 156-
1 p.
 artikel
251 206 Identification of novel targets for radiosensitisation of non-small cell lung cancer by secretome analysis Sharma, A.
 2014
 50 S6 p. 67-
1 p.
 artikel
252 111 Identification of peptides which could block PD-1 checkpoint for NSCLC immunotherapy Zhu, Y.
 2014
 50 S6 p. 39-
1 p.
 artikel
253 383 Identification of potent and selective tankyrase 1/2 inhibitors with activity in a subset of APC mutant colorectal cancer Guichard, S.M.
 2014
 50 S6 p. 123-
1 p.
 artikel
254 95 Identification of synthetic lethality compounds from natural products for cancers Ng, K.W.
 2014
 50 S6 p. 35-
1 p.
 artikel
255 180 Identifying and monitoring somatic mutations in cell free DNA of patients with metastatic melanoma Wisell, J.
 2014
 50 S6 p. 59-60
2 p.
 artikel
256 466 IGF2 drives IGF oncogenic signaling in HCC and emerges as a potential target for therapies Quetglas, I.M.
 2014
 50 S6 p. 152-
1 p.
 artikel
257 311 IGF-1R inhibition induced activation of Yes/SFK acts as a by-pass resistance pathway in rhabdomyosarcoma Wan, X.
 2014
 50 S6 p. 101-
1 p.
 artikel
258 317 IKKβ inhibition suppresses sphere formation and self-renewal of lung cancer initiating cells Carneiro-Lobo, T.
 2014
 50 S6 p. 103-
1 p.
 artikel
259 142 IL-17 as a novel molecular target for prostate cancer prevention de Angulo, A.
 2014
 50 S6 p. 49-
1 p.
 artikel
260 110 IL-6/STAT3/Fra-1 signaling axis promotes colorectal cancer aggressiveness through epithelial–mesenchymal transition Shao, J.
 2014
 50 S6 p. 39-
1 p.
 artikel
261 8 Imaging growth and anti-cancer activity in orthotopic patient derived tumors Baugher, M.
 2014
 50 S6 p. 9-
1 p.
 artikel
262 6 Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE tissue sections Mansfield, J.R.
 2014
 50 S6 p. 8-9
2 p.
 artikel
263 126 IMCgp100: A novel bi-specific biologic for the treatment of malignant melanoma Shingler, W.
 2014
 50 S6 p. 44-
1 p.
 artikel
264 137 Immune checkpoint blockade enhances measles virotherapy Engeland, C.E.
 2014
 50 S6 p. 48-
1 p.
 artikel
265 501 Immunological STAT3 knockdown associated with anti-tumor activity in pre-clinical models translates to clinical samples, suggesting immune modulation contributes to the clinical activity of AZD9150, a therapeutic STAT3 ASO McCoon, P.
 2014
 50 S6 p. 163-164
2 p.
 artikel
266 151 Impact of EGFR amplification pattern on the expression of miRNA-200c in primary glioblastoma multiforme Hidalgo, L. Muñoz
 2014
 50 S6 p. 51-52
2 p.
 artikel
267 237 Impact of phase 1 expansion cohorts on probability of success in phase 2 and time-to-drug-approval: analysis of 385 new drugs in oncology Bugano, D.
 2014
 50 S6 p. 79-80
2 p.
 artikel
268 262 Improved cytotoxic activity of Nor-β-lapachone-loaded PLGA microcapsules in PC3M prostate cancer cell line Pessoa, C.
 2014
 50 S6 p. 87-
1 p.
 artikel
269 595 Improving specificity of epigenetic therapy through combined targeting of DNA and histone methylation Sato, T.
 2014
 50 S6 p. 192-
1 p.
 artikel
270 74 Increased EDN1 expression mediates acquired resistance to the combination therapy of PI3K and MEK inhibitors for colorectal cancer Bhattacharya, B.
 2014
 50 S6 p. 29-
1 p.
 artikel
271 367 Induction of apoptosis and inhibition of angiogenesis by novel fusion protein – AD-O54.9 as a new preclinical strategy in cancer treatment Rozga, P.
 2014
 50 S6 p. 118-
1 p.
 artikel
272 380 Induction of apoptosis with a novel dual cIAP1/XIAP antagonist in models of melanoma Ward, G.
 2014
 50 S6 p. 122-
1 p.
 artikel
273 86 Influence of EGFR exon 19 mutation subtypes on survival outcomes in advanced stage Asian non-small cell lung cancer patients receiving TKI therapy Chowbay, B.
 2014
 50 S6 p. 32-
1 p.
 artikel
274 464 Influence of warm and cold ischemia on molecular patterns in clinical biospecimen Unger, F.T.
 2014
 50 S6 p. 151-152
2 p.
 artikel
275 510 Inhibition of STAT3 enhances the radiosensitising effect of temozolomide in malignant glioma cells in vitro and in vivo Kim, I.
 2014
 50 S6 p. 166-
1 p.
 artikel
276 293 Inhibition of the cell cycle regulated Cdc7 kinase pathway is an efficacious therapeutic approach for hematologic malignancies and solid tumors Santos, R.
 2014
 50 S6 p. 96-97
2 p.
 artikel
277 310 Inhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-101 Anderson, D.
 2014
 50 S6 p. 101-
1 p.
 artikel
278 346 Inhibition of Wnt pathway by novel thiazole-based Traf2- and Nck-interacting kinase (TNIK) inhibitor Uno, Y.
 2014
 50 S6 p. 112-
1 p.
 artikel
279 199 Inhibitor of differentiation 1 (Id1) expression in lung cancer cells and liver microenvironment is required for liver metastasis (LM) development from non-small cell lung cancer (NSCLC) by regulating EMT-related and proliferation-related proteins Castanon, E.
 2014
 50 S6 p. 65-
1 p.
 artikel
280 390 Inhibitors of EZH2 act synergistically with type 1 interferon to induce a potent interferon-stimulated gene response, triggering apoptosis in diffuse large B-cell lymphoma Bradley, B.
 2014
 50 S6 p. 125-
1 p.
 artikel
281 345 Interaction of plitidepsin with eEF1A in living tumor cells García, C.
 2014
 50 S6 p. 111-112
2 p.
 artikel
282 42 Interaction of SJG-136 with cognate sequences of oncogenic transcription factors Mantaj, J.
 2014
 50 S6 p. 19-
1 p.
 artikel
283 163 Interrogation of pharmacogenes in cancer patients using targeted DNA sequencing Innocenti, F.
 2014
 50 S6 p. 55-
1 p.
 artikel
284 578 Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis Leong, H.S.
 2014
 50 S6 p. 187-
1 p.
 artikel
285 531 In vitro and in vivo anti-tumor activity of ARQ 092, a potent and selective pan-AKT inhibitor Yu, Y.
 2014
 50 S6 p. 172-173
2 p.
 artikel
286 481 In vitro and vivo evaluation of the pan FGFR inhibitor ARQ 087 and selective pan AKT inhibitor ARQ 092 in endometrial cancer: potential for combination therapy Meade, J.
 2014
 50 S6 p. 156-157
2 p.
 artikel
287 203 Ionizing radiation induced phosphatidylserine externalization on endothelial cell surface – a potential target for vascular targeting Zhao, Z.
 2014
 50 S6 p. 66-
1 p.
 artikel
288 483 Irreversible covalent pan-FGFR inhibitors are highly efficacious against FGFR-dependent cancers Phan, V.T.
 2014
 50 S6 p. 157-
1 p.
 artikel
289 527 Is CRAF required for the maintenance of KRAS mutant non-small cell lung cancer? Russell, P.
 2014
 50 S6 p. 171-
1 p.
 artikel
290 477 Jab1/Csn5: a new player driving the resistance to HER2-targeted therapies for breast cancer Claret, F.
 2014
 50 S6 p. 155-
1 p.
 artikel
291 328 Jagged1 expression and its relevance in metastatic progression of breast cancers Bednarz-Knoll, N.
 2014
 50 S6 p. 106-107
2 p.
 artikel
292 235 Kinetic analysis of dynamic 11C thymidine PET imaging studies: Compartmental and nonparametric approaches Murphy, S.
 2014
 50 S6 p. 79-
1 p.
 artikel
293 234 Kinetic analysis of dynamic 11C-verapamil PET study: Compartmental v adaptive mixture models comparison Hernandez, F.
 2014
 50 S6 p. 79-
1 p.
 artikel
294 358 Knockdown of beta-catenin with dicer-substrate siRNAs down-regulates Wnt/beta-catenin pathway signaling Pursell, N.
 2014
 50 S6 p. 115-116
2 p.
 artikel
295 8LBA Activity of the PARP inhibitor olaparib in ATM-deficient gastric cancer: from preclinical models to the clinic Hodgson, D.
 2014
 50 S6 p. 198-
1 p.
 artikel
296 9LBA Antitumor activity of ASP8273, an irreversible mutant selective EGFR-TKI, in NSCLC patients with tumors harboring EGFR activating mutations and T790M resistance mutation Murakami, H.
 2014
 50 S6 p. 198-
1 p.
 artikel
297 4LBA A phase 1 study of first-in-class microRNA-34 mimic, MRX34, in patients with hepatocellular carcinoma or advanced cancer with liver metastasis Beg, M.
 2014
 50 S6 p. 196-
1 p.
 artikel
298 1LBA Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies Pollyea, D.A.
 2014
 50 S6 p. 195-
1 p.
 artikel
299 3LBA Initial report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 Infante, J.
 2014
 50 S6 p. 195-196
2 p.
 artikel
300 10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer Soria, J.
 2014
 50 S6 p. 199-
1 p.
 artikel
301 7LBA Phase 1 dose-expansion study of AMG 900, a pan-Aurora kinase inhibitor, in adult patients with advanced taxane-resistant solid tumors Markman, B.
 2014
 50 S6 p. 197-198
2 p.
 artikel
302 6LBA Phase 1 first-in-human study of the enhancer of zeste-homolog 2 (EZH2) histone methyl transferase inhibitor E7438 as a single agent in patients with advanced solid tumors or B cell lymphoma Ribrag, V.
 2014
 50 S6 p. 197-
1 p.
 artikel
303 11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer Tabernero, J.
 2014
 50 S6 p. 199-
1 p.
 artikel
304 5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies Stathis, A.
 2014
 50 S6 p. 196-
1 p.
 artikel
305 2LBA The identification of potent and selective inhibitors of oncogenes in medullary thyroid carcinoma and lung adenocarcinoma disease models Fritzl, S.
 2014
 50 S6 p. 195-
1 p.
 artikel
306 261 Lesion characterization with ferumoxytol MRI in patients with advanced solid tumors and correlation with treatment response to MM-398, nanoliposomal irinotecan (nal-IRI) Ramanathan, R.K.
 2014
 50 S6 p. 87-
1 p.
 artikel
307 Letter of Welcome Soria, Jean-Charles
 2014
 50 S6 p. vii-
1 p.
 artikel
308 161 Leveraging a novel DNA barcoding platform for integrated profiling and pharmacodynamic readouts Castro, C.
 2014
 50 S6 p. 54-
1 p.
 artikel
309 75 Loss of PTEN leads to acquired resistance to the PI3Ka inhibitor BYL719: a case of convergent evolution under selective therapeutic pressure Castel, P.
 2014
 50 S6 p. 29-
1 p.
 artikel
310 55 Low, frequent doses of PM060184 induce remarkable in vivo antitumor activity Aviles, P.
 2014
 50 S6 p. 23-
1 p.
 artikel
311 391 LOXO-101, a pan TRK inhibitor, for the treatment of TRK-driven cancers Winski, S.
 2014
 50 S6 p. 125-
1 p.
 artikel
312 494 LPA6 promotes growth and tumorigenicity of hepatocellular carcinoma via activation of PIM-3 proto-oncogene kinase Lopane, C.
 2014
 50 S6 p. 161-
1 p.
 artikel
313 47 Lurbinectedin (PM01183) specifically targets RNA Pol II for degradation via the proteasome pathway in a transcription and TC-NER dependent fashion Santamaria, G.
 2014
 50 S6 p. 20-21
2 p.
 artikel
314 562 Lysophosphatidic acid-induced breast cancer metastasis depends on LPA1/ZEB1/miR-21-activation pathway Sahay, D.
 2014
 50 S6 p. 182-
1 p.
 artikel
315 118 Major synergy between Coxsackievirus A21 (CAVATAK™) and radiotherapy or chemotherapy in bladder cancer Simpson, G.R.
 2014
 50 S6 p. 41-42
2 p.
 artikel
316 574 M-COPA, a Golgi disruptor, inhibits cell surface expression of MET protein and exhibits antitumor activity against MET-addicted cancers Ohashi, Y.
 2014
 50 S6 p. 185-186
2 p.
 artikel
317 5 Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib Srinivasan, R.
 2014
 50 S6 p. 8-
1 p.
 artikel
318 591 Mechanistic analysis of reversible FASN inhibition in preclinical tumor models identifies highly susceptible tumor types and enriches biomarker discovery for clinical applications Heuer, T.S.
 2014
 50 S6 p. 190-191
2 p.
 artikel
319 445 MEK inhibition enhances gemcitabine efficacy by increasing MDM2-mediated ubiquitination and degradation of RRM1 Vena, F.
 2014
 50 S6 p. 146-
1 p.
 artikel
320 543 MEK1/2 specific inhibitor, SMK-17 selectively induces apoptosis in β-catenin mutated tumors Kiga, M.
 2014
 50 S6 p. 176-
1 p.
 artikel
321 282 Membrane anchorage of Stat3 via artificial protein lipidation Avadisian, M.
 2014
 50 S6 p. 93-
1 p.
 artikel
322 375 MER as a novel therapeutic target in colorectal cancer Wong, K.
 2014
 50 S6 p. 120-121
2 p.
 artikel
323 298 Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression Kim, C.
 2014
 50 S6 p. 98-
1 p.
 artikel
324 44 Metformin and its impact on gastric cancer patients survival after gastrectomy Lee, C.K.
 2014
 50 S6 p. 20-
1 p.
 artikel
325 205 Metformin to modulate AMP-kinase and enhance chemotherapy and radiotherapy in non-small cell lung cancer Troncone, M.J.
 2014
 50 S6 p. 67-
1 p.
 artikel
326 54 MGMT methylation assessed by methyl-BEAMing technique is a prognostic and predictive biomarker in glioblastoma and metastatic colorectal cancer patients Barault, L.
 2014
 50 S6 p. 23-
1 p.
 artikel
327 502 MI130004, an antibody–drug conjugate including a novel payload of marine origin: Evidences of in vivo activity Aviles, P.M.
 2014
 50 S6 p. 164-
1 p.
 artikel
328 256 Minicell packaged targeted delivery of shRNA to cancer cells Jivrajani, M.
 2014
 50 S6 p. 85-86
2 p.
 artikel
329 20 miR-25 is a key regulator of prostate cancer invasiveness by modulation of the cross-talk between Notch and TGF-β signaling Zoni, E.
 2014
 50 S6 p. 12-13
2 p.
 artikel
330 545 MiRNAs related to KRAS mutational status in resectable non-small cell lung cancer Gallach, S.
 2014
 50 S6 p. 177-
1 p.
 artikel
331 76 Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors Marusiak, A.A.
 2014
 50 S6 p. 29-30
2 p.
 artikel
332 14 Mixeno mouse models for in vivo evaluation of anti-human cancer immunotherapeutics Zhang, J.
 2014
 50 S6 p. 11-
1 p.
 artikel
333 438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen Harms, B.D.
 2014
 50 S6 p. 144-
1 p.
 artikel
334 570 Modulation of chromatin-related processes in DNA damage response as a potential strategy to treat acute myeloid leukemia Chomej, K.
 2014
 50 S6 p. 184-
1 p.
 artikel
335 172 Modulation of estrogen-dependent transcription by cohesin in MCF7 human breast adenocarcinoma cells Dasgupta, T.
 2014
 50 S6 p. 57-
1 p.
 artikel
336 243 Modulation of PI3K/mTOR pathway following PARP inhibition in small cell lung cancer Cardnell, R.J.
 2014
 50 S6 p. 81-82
2 p.
 artikel
337 275 Modulation of PIP2 levels through small molecule inhibition of PIP5K Andrews, D.
 2014
 50 S6 p. 91-
1 p.
 artikel
338 254 Molecular analysis in breast cancer: correlation with Immunohistochemical classification and pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) Baulies, S.
 2014
 50 S6 p. 85-
1 p.
 artikel
339 189 Molecular and pharmacological characterization of primary mesothelioma tumor cell lines orthotopically xenografted in nude mice Pisano, C.
 2014
 50 S6 p. 62-
1 p.
 artikel
340 460 Molecular biomarkers of inflammatory signature in melanoma Ekmekcioglu, S.
 2014
 50 S6 p. 150-
1 p.
 artikel
341 421 Molecular profiling for factors predicting sensitivity or resistance to therapy in relapsed child cancer Saletta, F.
 2014
 50 S6 p. 135-
1 p.
 artikel
342 184 Molecular profiling of heterogeneous tumor cells Chenchik, A.
 2014
 50 S6 p. 60-
1 p.
 artikel
343 225 Molecular targets of interest to the NCI PREVENT cancer preclinical drug development program Shoemaker, R.H.
 2014
 50 S6 p. 76-
1 p.
 artikel
344 436 Monitoring activity of RXDX-101 in Phase 1/2 patients using a pharmacodynamic assay for TrkA activation Murphy, D.
 2014
 50 S6 p. 143-144
2 p.
 artikel
345 454 Monitoring therapy response and resistance mutations in circulating RNA and DNA of plasma from patients with malignant melanoma Enderle, D.
 2014
 50 S6 p. 149-
1 p.
 artikel
346 7 Mouse clinical trial – A new preclinical study concept using patient-derived xenografts Vuaroqueaux, V.
 2014
 50 S6 p. 9-
1 p.
 artikel
347 153 Moving beyond in vitro models and addressing the challenges of pooled RNAi screens in mouse xenografts Tedesco, D.
 2014
 50 S6 p. 52-
1 p.
 artikel
348 10 mTOR inhibition with everolimus – a novel treatment option for head and neck cancer identified in a translational research study using patient-derived xenografts Klinghammer, K.
 2014
 50 S6 p. 10-
1 p.
 artikel
349 357 Multi-color flow cytometry immunophenotyping for detection of CSC in NSCLC Martinez-Romero, A.
 2014
 50 S6 p. 115-
1 p.
 artikel
350 227 Multiplexed ICE COLD-PCR: A mutation detection methodology for achieving sensitivities of <0.01% using either Sanger or NGS Wu, G.
 2014
 50 S6 p. 76-77
2 p.
 artikel
351 339 NAMPT inhibition as strategy to impair tumor growth Cerezo, A.
 2014
 50 S6 p. 110-
1 p.
 artikel
352 361 Nanoformulations of the PARP inhibitors olaparib and BMN 673 for cancer nanotherapy Sridhar, S.
 2014
 50 S6 p. 116-
1 p.
 artikel
353 588 Neddylation as a therapeutic target in refractory pediatric malignancies: Evaluation of the activating enzyme inhibitor MLN4924 Ruan, Y.
 2014
 50 S6 p. 189-190
2 p.
 artikel
354 159 Neoadjuvant chemotherapy in breast cancer patients induces expression of miR-34a and miR-122 Freres, P.
 2014
 50 S6 p. 53-54
2 p.
 artikel
355 374 Neuregulin 1 (NRG1) expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models Meetze, K.
 2014
 50 S6 p. 120-
1 p.
 artikel
356 196 Neuropilin 2 (NRP2) modifies CXCL12/CXCR4 signaling and promotes lymph node metastases in colon cancer Schneider, H.
 2014
 50 S6 p. 64-
1 p.
 artikel
357 413 Next-generation sequencing identifies the mechanism of tumourigenesis caused by loss of SMARCB1 in malignant rhabdoid tumours Finetti, M.A.
 2014
 50 S6 p. 132-
1 p.
 artikel
358 12 Next generation sequencing (NGS) guided therapy prediction for the treatment of glioblastoma multiforme (GBM) Sarkaria, J.
 2014
 50 S6 p. 10-11
2 p.
 artikel
359 64 Nifuroxazide halogenic derivatives induce ROS-mediated apoptosis and display antitumor activity against metastatic melanoma de Farias, C. Fernandez
 2014
 50 S6 p. 26-
1 p.
 artikel
360 239 Niraparib, a selective PARP 1/2 inhibitor, is efficacious in pre-clinical models of small-cell lung cancer Wang, Y.
 2014
 50 S6 p. 80-81
2 p.
 artikel
361 31 N-Myc amplification sensitizes tumor cells to inhibition by Danusertib, an Aurora kinase inhibitor Carpinelli, P.
 2014
 50 S6 p. 16-
1 p.
 artikel
362 589 N-myc downstream regulated gene 1 (NDRG1) as a novel anti-angiogenic and therapeutic target for VEGF/VEGF receptor signaling by vascular endothelial cells Watari, K.
 2014
 50 S6 p. 190-
1 p.
 artikel
363 561 Nonclinical characterization of the first in class investigational ubiquitin activating enzyme inhibitor MLN7243 in cellular and in vivo models of cancer in support of a phase I study Milhollen, M.
 2014
 50 S6 p. 181-182
2 p.
 artikel
364 424 Nonclinical safety assessment of a humanized anti-OX40 agonist antibody, MOXR0916 Prell, R.
 2014
 50 S6 p. 136-
1 p.
 artikel
365 385 Noninvasive monitoring of acquired EGFR-T790M mutation and discovery of its heterogeneity in patients with advanced NSCLC treated with EGFR-TKI Ye, X.
 2014
 50 S6 p. 123-124
2 p.
 artikel
366 443 Notch3-targeted antibody drug conjugates have superior preclinical efficacy to Notch signaling inhibitors Geles, K.G.
 2014
 50 S6 p. 145-
1 p.
 artikel
367 267 Novel adjuvant therapy with leptin peptide receptor antagonist-2 conjugated to nanoparticles (IONP-LPrA2) to minimize chemoresistance in triple negative breast cancer Harmon, T.
 2014
 50 S6 p. 89-
1 p.
 artikel
368 322 Novel alternative splice variants as potential biomarkers and therapeutic targets in aggressive prostate cancer in men of African descent Patierno, S.
 2014
 50 S6 p. 105-
1 p.
 artikel
369 212 Novel anti-tumor activity of targeted LSD1 inhibition by GSK2879552 Mohammad, H.
 2014
 50 S6 p. 72-
1 p.
 artikel
370 22 Novel combination therapy, TAS-102 combined with the anti-EGFR antibody or the anti-VEGF antibody showed therapeutic benefit toward colorectal cancer xenografts Ishida, K.
 2014
 50 S6 p. 13-
1 p.
 artikel
371 274 Novel cysteine derivatives for the next generation anticancer agents acting on KSP Ogo, N.
 2014
 50 S6 p. 91-
1 p.
 artikel
372 281 Novel hybrid drug design strategy to circumvent erlotinib resistance and to optimize its pharmacokinetic properties for treating lung cancer Poon, D.C.S.
 2014
 50 S6 p. 93-
1 p.
 artikel
373 576 Novel inhibitors of peritoneal seeding Shen, Y.
 2014
 50 S6 p. 186-
1 p.
 artikel
374 571 Novel potent inhibitors of the Histone Demethylase KDM1A: Synthesis, pharmacological evaluation and in vivo activity Varasi, M.
 2014
 50 S6 p. 185-
1 p.
 artikel
375 447 Novel, quantitative in vivo shRNA screening approach identifies new molecular targets to block cancer metastasis Willetts, L.
 2014
 50 S6 p. 147-
1 p.
 artikel
376 71 Novel regulation of estrogen receptor transcription by the PI3K pathway Toska, E.
 2014
 50 S6 p. 28-
1 p.
 artikel
377 116 Novel targets for antibody–drug conjugate therapy Grandi, A.G.
 2014
 50 S6 p. 41-
1 p.
 artikel
378 318 Novel therapeutic targets for ARID1A mutant ovarian clear cell carcinoma (OCCC) Miller, R.E.
 2014
 50 S6 p. 103-104
2 p.
 artikel
379 170 Novel, ultra-deep next-generation sequencing for BRAF mutation testing using small amount of cell-free DNA from plasma of patients with advanced cancers Janku, F.
 2014
 50 S6 p. 57-
1 p.
 artikel
380 26 NPD926, a small molecule inducer of reactive oxygen species, kills cancer cells via glutathione depletion Kawamura, T.
 2014
 50 S6 p. 14-
1 p.
 artikel
381 368 NP137, the first humanized monoclonal antibody directed against netrin-1, exhibits antitumor activity by inducing dependence receptors-mediated cell death Delcros, J.G.
 2014
 50 S6 p. 118-119
2 p.
 artikel
382 72 Nrf2 as a molecular target in overwhelming chemoresistance in breast cancer therapy Samadi, N.
 2014
 50 S6 p. 28-
1 p.
 artikel
383 550 Nupharidine inhibits NF-kB activity, induces apoptosis and has synergistic cytotoxic activity with cisplatin and etoposide Gopas, J.
 2014
 50 S6 p. 178-179
2 p.
 artikel
384 432 ODM-203, a novel, selective and balanced FGFR and VEGFR inhibitor with strong anti-tumor activity in FGFR- and VEGFR-dependent cancer models Holmström, T.
 2014
 50 S6 p. 142-
1 p.
 artikel
385 350 Oncogenic Ras mutants differentially utilize PLC-dependent calcium flux and PKC activation for MAPK signaling Pitt, C.
 2014
 50 S6 p. 113-
1 p.
 artikel
386 314 Optimal sequencing schedules for combining BRAF inhibition with BCL-2 inhibition Schalck, A.
 2014
 50 S6 p. 102-
1 p.
 artikel
387 400 Optimization of novel pyrido[2,3-b]pyrazine based small molecule fibroblast growth factor receptor 1, 2, 3 & 4 (FGFR) inhibitors into a potential clinical candidate Angibaud, P.
 2014
 50 S6 p. 128-
1 p.
 artikel
388 572 Oral panobinostat in patients with advanced tumors and impaired renal function: Relationship between pharmacokinetics and key safety parameters Porro, M.
 2014
 50 S6 p. 185-
1 p.
 artikel
389 567 OTX015, a BET-bromodomain (BET-BRD) inhibitor, potentiates the in vitro effects of chemotherapy drugs and targeted agents in human leukemic cell lines Astorgues-Xerri, L.
 2014
 50 S6 p. 183-
1 p.
 artikel
390 564 OTX015, a novel BET-BRD inhibitor is active in non-small-cell lung cancer cell (NSCLC) lines harboring different oncogenic mutations Riveiro, M.
 2014
 50 S6 p. 182-
1 p.
 artikel
391 469 OTX015, a novel BET-bromodomain (BET-BRD) inhibitor, is a promising anticancer agent for human glioblastoma Ouafik, L.
 2014
 50 S6 p. 153-
1 p.
 artikel
392 220 Overcoming drug-resistance in multiple myeloma by XPO1 inhibitor combination therapy Turner, J.
 2014
 50 S6 p. 74-75
2 p.
 artikel
393 258 Pancreatic cancer cells expressing the OATP1B3 transporter show promising sensitivity to the highly cytotoxic microcystin-LR molecule Kounnis, V.
 2014
 50 S6 p. 86-
1 p.
 artikel
394 194 Pancreatic ductal organoids as a new platform for drug discovery Ponz-Sarvise, M.
 2014
 50 S6 p. 63-
1 p.
 artikel
395 246 PARP inhibitors trap PARP1 onto damaged DNA via catalytic inhibition and not by an allosteric mechanism Hopkins, T.
 2014
 50 S6 p. 82-83
2 p.
 artikel
396 354 PCR-based assay for BRAFV600 mutation analysis in ctDNA: clinical results from plasma and serum samples Gonzalez-Cao, M.
 2014
 50 S6 p. 114-
1 p.
 artikel
397 410 Pediatric Preclinical Testing Program (PPTP) Evaluation of the p53-MDM2 Antagonist MK-8242 Smith, M.
 2014
 50 S6 p. 131-
1 p.
 artikel
398 21 Pharmacogenomics of mithramycin in thoracic malignancies Figg, W.
 2014
 50 S6 p. 13-
1 p.
 artikel
399 478 Pharmacological disruption of the Astrocytic Elevated Gene-1 (AEG1) in anticancer intervention: PB0412_3 (PB03) as a first-in-class AEG1 interacting agent Jimeno, J.
 2014
 50 S6 p. 156-
1 p.
 artikel
400 499 Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma Dreyling, M.
 2014
 50 S6 p. 162-163
2 p.
 artikel
401 551 Phase 1B study of CC-486 (oral azacitidine) in tumors associated with a viral etiology von Hoff, D.D.
 2014
 50 S6 p. 179-
1 p.
 artikel
402 253 Phase 1 correlative study of ARQ761, a β-lapachone analogue that promotes NQ01-mediated programmed cancer cell necrosis Gerber, D.
 2014
 50 S6 p. 84-85
2 p.
 artikel
403 382 Phase Ib study of oral dual-PI3K/mTOR inhibitor GDC-0980 in combination with capecitabine and mFOLFOX6 + bevacizumab in patients with advanced solid tumors and colorectal cancer Rosen, L.
 2014
 50 S6 p. 122-123
2 p.
 artikel
404 34 Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors or lymphoma Lin, C.
 2014
 50 S6 p. 17-
1 p.
 artikel
405 65 Phase II drug metabolism UGT1A enzyme affects cellular response of colon cancer cells to antitumor triazoloacridinone C-1305 treatment Augustin, E.
 2014
 50 S6 p. 26-
1 p.
 artikel
406 141 Phase I study of ipilimumab with stereotactic radiosurgery for melanoma patients with brain metastases Shi, W.
 2014
 50 S6 p. 49-
1 p.
 artikel
407 23 Phase I study of lurbinectedin (PM01183) administered on days (D) 1 & 8 every 3 weeks (q3wk) in patients (pts) with solid tumors Ratain, M.J.
 2014
 50 S6 p. 13-14
2 p.
 artikel
408 586 Phase I study of pan-histone deacetylase inhibitor abexinostat in combination with cisplatin in patients with advanced solid tumors Campone, M.
 2014
 50 S6 p. 189-
1 p.
 artikel
409 216 Phase I study of panobinostat and fractionated stereotactic re-irradiation therapy (FSRT) for recurrent high grade gliomas Shi, W.
 2014
 50 S6 p. 73-
1 p.
 artikel
410 219 Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients: A novel approach to treat HPV related malignancies? Deutsch, E.
 2014
 50 S6 p. 74-
1 p.
 artikel
411 506 Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer Sachdev, J.
 2014
 50 S6 p. 165-
1 p.
 artikel
412 440 Phenotypic alteration in a highly metastatic variant of the MDA-MB-231 cell line: role of Annexin A1 Tu, Y.
 2014
 50 S6 p. 144-145
2 p.
 artikel
413 362 Phenotypic plasticity in epithelial progenitors and mesenchymal carcinoma is regulated by Axl signaling Engelsen, A.
 2014
 50 S6 p. 117-
1 p.
 artikel
414 39 Phytochemical indole-3-carbinol synergizes strongly with fludarabine and induces p53-dependent and -independent cell death in chronic lymphocytic leukemia cells irrespective of their IGHV mutation state and treatment resistances Perez-Chacon, G.
 2014
 50 S6 p. 18-
1 p.
 artikel
415 386 PI3K and MEK inhibitor combination toxicities and relative dose intensity: Vall d'Hebron experience Azaro, A.
 2014
 50 S6 p. 124-
1 p.
 artikel
416 101 PIK3CA mutation-targeting compounds analyses using NCI60 cell line panel Bando, H.
 2014
 50 S6 p. 36-37
2 p.
 artikel
417 304 PI3′-Kinase inhibition forestalls the development of drug resistance in BRAFV600E/PTENNull melanoma Deuker, M.
 2014
 50 S6 p. 100-
1 p.
 artikel
418 439 PI3K/mTOR inhibitor VS-5584 targets cancer stem cells and prevents tumor regrowth after chemotherapy in preclinical models of small cell lung cancer Kolev, V.
 2014
 50 S6 p. 144-
1 p.
 artikel
419 437 PIM kinase inhibitor AZD1208 sensitises SCLC to BH3 mimetic AZD4320 Sloane, R.
 2014
 50 S6 p. 144-
1 p.
 artikel
420 365 Pim-1 kinase: Validated as a therapeutic cancer target for MYC-driven tumours Renner, O.
 2014
 50 S6 p. 118-
1 p.
 artikel
421 58 Pipecolidepsin A, Stellatolide A and Irvalec: New cyclodepsipeptides of marine origin with antitumor activity Molina-Guijarro, J.M.
 2014
 50 S6 p. 24-
1 p.
 artikel
422 150 Pirin downregulates E-cadherin gene expression and contributes to EMT Komai, K.
 2014
 50 S6 p. 51-
1 p.
 artikel
423 453 Plasma metabolomic signature of novel signal transduction inhibitors from preclinical identification to clinical validation Ang, J.E.
 2014
 50 S6 p. 148-149
2 p.
 artikel
424 52 Platinum(IV) derivatives of oxaliplatin: Cellular effects and in vivo potency Göschl, S.
 2014
 50 S6 p. 22-
1 p.
 artikel
425 377 Plucked hair as a platform for monitoring pharmacodynamic and mechanistic consequences of clinical exposure to the Wnt/beta-catenin inhibitor PRI-724 Miele, G.
 2014
 50 S6 p. 121-
1 p.
 artikel
426 284 Poly(ADP-ribose) glycohydrolase (PARG) inhibitors increase nuclear poly(ADP-ribose) after methylating DNA damage Jordan, A.
 2014
 50 S6 p. 94-
1 p.
 artikel
427 418 Population pharmacokinetics of intravenous bolus 5-fluorouracil in a phase I trial for children and young adults with recurrent ependymoma Turner, D.C.
 2014
 50 S6 p. 133-134
2 p.
 artikel
428 321 Potent and selective inhibition of EZH2 by AU-2121 leads to significant tumor growth inhibition in mutant EZH2 dependent non-Hodgkin lymphoma Ahmed, S.
 2014
 50 S6 p. 104-105
2 p.
 artikel
429 490 Potent and selective inhibitors of the KRAS-signaling nanocluster protein, CNKSR1, block oncogenic KRAS signaling and mut-KRAS cell growth Kirkpatrick, L.
 2014
 50 S6 p. 160-
1 p.
 artikel
430 286 Potent and selective non-sulfamate-containing small molecule inhibitors of the ubiquitin activating enzyme Paiva, S.
 2014
 50 S6 p. 95-
1 p.
 artikel
431 474 Potentiation of oxaliplatin in colon cancer by JNK inhibition Vasilevskaya, I.
 2014
 50 S6 p. 154-155
2 p.
 artikel
432 316 Potent, partial agonists at ERalpha as selective estrogen mimics for treatment of tamoxifen-resistant breast cancer Thatcher, G.
 2014
 50 S6 p. 103-
1 p.
 artikel
433 450 Precise gene editing of mutant NRAS using CRISPR to determine sensitivity to trametinib Hose, C.
 2014
 50 S6 p. 147-148
2 p.
 artikel
434 113 Preclinical activity and pharmacodynamic biomarkers of W014A, a PD-1 decoy peptide blocking both PD-1 immune checkpoint ligands, PD-L1 and PD-L2 Bailly, C.
 2014
 50 S6 p. 40-
1 p.
 artikel
435 138 Preclinical activity and safety of MGD006, a CD123xCD3 Bispecific DART® molecule for the treatment of hematological malignancies Moore, P.
 2014
 50 S6 p. 48-
1 p.
 artikel
436 547 Preclinical activity of Debio 1347, an oral selective FGFR1, 2, 3 inhibitor, in models harboring FGFR alterations Chessex, A. Vaslin
 2014
 50 S6 p. 177-178
2 p.
 artikel
437 340 Preclinical activity of the VEGFR, FGFR and PDGFR inhibitor lucitanib in FGFR2 aberrant endometrial and gastric cancer models Guffanti, F.
 2014
 50 S6 p. 110-
1 p.
 artikel
438 166 Pre-clinical and clinical activity of Anti-DLL4 (demcizumab) in combination with gemcitabine plus nab-paclitaxel in pancreatic cancer Hidalgo, M.
 2014
 50 S6 p. 55-56
2 p.
 artikel
439 209 Pre-clinical and translational pharmacology, pharmacokinetics and pharmacodynamics for a humanized anti-OX40 antibody MOXR0916, a T-cell agonist in the treatment of solid tumors Sukumaran, S.
 2014
 50 S6 p. 71-
1 p.
 artikel
440 223 Preclinical assessment of nintedanib for chemoprevention in hepatocellular carcinoma Tovar, V.
 2014
 50 S6 p. 75-
1 p.
 artikel
441 459 Preclinical characterization of CC-115, a novel inhibitor of DNA-PK and mTOR kinase currently under clinical investigation Mortensen, D.S.
 2014
 50 S6 p. 150-
1 p.
 artikel
442 152 Preclinical characterization of MM-151, an oligoclonal antibody therapeutic that targets EGFR by three distinct mechanisms of action King, A.
 2014
 50 S6 p. 52-
1 p.
 artikel
443 330 Preclinical development of BIS-1602, first in class growth hormone releasing hormone antagonist Maxuitenko, Y.Y.
 2014
 50 S6 p. 107-
1 p.
 artikel
444 249 Preclinical efficacy of the PARP inhibitor rucaparib (CO-338/AG014699/PF-01367338) in pancreatic cancer models with homologous recombination deficiencies (HRD) Robillard, L.
 2014
 50 S6 p. 83-
1 p.
 artikel
445 497 Preclinical evaluation of dimeric IAP proteins inhibitor APG-1387, in triple negative breast cancer both in vitro and in vivo Wang, G.
 2014
 50 S6 p. 162-
1 p.
 artikel
446 565 Preclinical evaluation of OTX015, a novel BET-BRD inhibitor, on small cell lung cancer (SCLC) cell lines Ijaz, N.
 2014
 50 S6 p. 183-
1 p.
 artikel
447 255 Pre-clinical in vivo characterization of MLN7243, an investigational ubiquitin activating enzyme inhibitor, in solid tumor models Traore, T.
 2014
 50 S6 p. 85-
1 p.
 artikel
448 493 Preclinical pharmacokinetic (PK)/pharmacodynamic (PD)/Efficacy modeling for MLN2480, an investigational pan-RAF kinase inhibitor, in A375 and SKMEL-2 human melanoma xenografts Patel, M.
 2014
 50 S6 p. 161-
1 p.
 artikel
449 300 Preclinical pharmacologic characterization of GSK2849330, a monoclonal AccretaMab® antibody with optimized ADCC and CDC activity directed against HER3 Clarke, N.
 2014
 50 S6 p. 98-99
2 p.
 artikel
450 457 Preclinical pharmacology of AZD5312, a generation 2.5 antisense oligonucletotide targeting the androgen receptor with differentiated activity from enzalutamide Davies, B.R.
 2014
 50 S6 p. 150-
1 p.
 artikel
451 130 Preclinical results of ProCervix, a first in class, first in indication therapeutic vaccine targeting HPV16/18 infected women Esquerre, M.
 2014
 50 S6 p. 45-
1 p.
 artikel
452 544 Preclinical studies of a dual Bcl-2/Bcl-xL inhibitor APG-1252 with strong anti-tumor efficacy and significantly reduced platelet toxicity Wang, H.
 2014
 50 S6 p. 176-177
2 p.
 artikel
453 Presenting Authors List 2014
 50 S6 p. 201-204
4 p.
 artikel
454 265 Pretargeted nanoparticles to deliver both chemotherapeutics and radiation for the treatment of lymphoma Fang, C.
 2014
 50 S6 p. 88-
1 p.
 artikel
455 496 Prevalence of MET amplification, MET expression, and MET-related genomic alterations in non-small cell lung cancer (NSCLC) Ang, A.L.
 2014
 50 S6 p. 161-162
2 p.
 artikel
456 289 Progress in drugging CYP1A1, 1B1 and CYP2W1 overexpressed in cancer Pors, K.
 2014
 50 S6 p. 95-
1 p.
 artikel
457 353 Protein expression for receptor activator of NFkB (RANK) and its ligand (RANKL) in non-small cell lung cancer (NSCLC) D'Arcangelo, M.
 2014
 50 S6 p. 114-
1 p.
 artikel
458 553 PRPF6, a tri-snRNP spliceosome protein, regulates the alternative splicing of a distinct oncogenic ZAK variant and promotes colon tumor growth Firestein, R.
 2014
 50 S6 p. 179-
1 p.
 artikel
459 463 PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs Prahallad, A.
 2014
 50 S6 p. 151-
1 p.
 artikel
460 492 Quantification of exportin-1 (XPO1) occupancy by selective inhibitors of nuclear export (SINE) Crochiere, M.
 2014
 50 S6 p. 160-
1 p.
 artikel
461 149 Quantitative mutational assessment of circulating tumor DNA using massively parallel deep sequencing in plasma and urine from advanced colorectal cancer patients Poole, J.C.
 2014
 50 S6 p. 51-
1 p.
 artikel
462 79 Quantitative proteomics as a tool to identify resistance mechanisms in erlotinib-resistant subclones of the non-small cell lung cancer cell line HCC827 Jacobsen, K.
 2014
 50 S6 p. 30-
1 p.
 artikel
463 56 Radiosensitizing effect of sodium metaarsenite in a metastatic brain tumor model Kang, W.Y.
 2014
 50 S6 p. 23-24
2 p.
 artikel
464 63 Radium-223 dichloride – Efficacy and mode-of-action in a mouse model of prostate cancer bone metastasis Suominen, M.I.
 2014
 50 S6 p. 25-26
2 p.
 artikel
465 188 RANBP2 knock-down is synthetic lethal with BRAF V600E in colon cancer Vecchione, L.
 2014
 50 S6 p. 61-62
2 p.
 artikel
466 173 Ras-mediated activation of mitogen-activated protein kinase pathway unleashes basement membrane damaging activity of serine protease hepsin Tervonen, T.
 2014
 50 S6 p. 57-58
2 p.
 artikel
467 148 RAS synthetic lethal interactions from yeast to human cells van Wageningen, S.
 2014
 50 S6 p. 51-
1 p.
 artikel
468 582 Rational for targeting chromatin-modifying genes in clear-cell renal cell carcinomas Malouf, G.
 2014
 50 S6 p. 188-
1 p.
 artikel
469 431 Real-time pharmacokinetic (PK) results from an ongoing randomized, parallel-dose phase 1 study of onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers Lokiec, F.
 2014
 50 S6 p. 142-
1 p.
 artikel
470 384 REDX04988, a novel dual B-RAF/C-RAF inhibitor and a potential therapeutic for BRAF-mutant colorectal cancer Rainard, J.
 2014
 50 S6 p. 123-
1 p.
 artikel
471 143 Regional bias of intratumoral genetic heterogeneity of nucleotide repeats in colon cancers with microsatellite instability An, C.
 2014
 50 S6 p. 49-50
2 p.
 artikel
472 82 Regorafenib resistance in colorectal carcinoma is associated with enhanced expression of type II interleukin 1 receptor and reversed by MEK/ERK inhibitor Mar, A.C.
 2014
 50 S6 p. 31-
1 p.
 artikel
473 140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475) Daud, A.
 2014
 50 S6 p. 48-49
2 p.
 artikel
474 32 Replication stress is a determinant of synergy between gemcitabine and Chk1 inhibition Koh, S.B.
 2014
 50 S6 p. 16-
1 p.
 artikel
475 482 Repurposing the antihelminthic mebendazole as a hedgehog inhibitor Larsen, A.R.
 2014
 50 S6 p. 157-
1 p.
 artikel
476 176 Resolvin D2 has mitogenic activity in estrogen receptor positive breast cancer cell lines via activation of estrogen receptor Al-Zaubai, N.
 2014
 50 S6 p. 58-59
2 p.
 artikel
477 217 Results of a phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma Kang, Y.K.
 2014
 50 S6 p. 73-74
2 p.
 artikel
478 416 Results of phase I study of bolus 5-fluorouracil in children and young adults with recurrent ependymoma Wright, K.D.
 2014
 50 S6 p. 133-
1 p.
 artikel
479 238 Reversal of primary and acquired PARP-inhibitor resistance in BRCA-mutated triple-negative breast cancers by inhibition of transcriptional cyclin-dependent kinases (CDKs) Johnson, S.
 2014
 50 S6 p. 80-
1 p.
 artikel
480 539 Reversing the epithelial to mesenchymal transition with N-myc downstream regulated gene-1 and novel iron chelators in pancreatic cancer Fouani, L.
 2014
 50 S6 p. 175-
1 p.
 artikel
481 399 Rho-GTPase, RAC1 and Cdc42 mediates Wnt–beta-catenin signals for metastasis associated phenotypes in TNBC: A proof of concept study Dey, N.
 2014
 50 S6 p. 128-
1 p.
 artikel
482 335 RICTOR amplification as a novel molecular target for the treatment of lung cancer Cheng, H.
 2014
 50 S6 p. 108-109
2 p.
 artikel
483 558 RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer Wendel, H.
 2014
 50 S6 p. 181-
1 p.
 artikel
484 423 RNA helicase A is essential for 1p36 gene KIF1Bβ tumor suppression in neuroblastomas Chen, Z.X.
 2014
 50 S6 p. 135-
1 p.
 artikel
485 309 RNA sequencing and in silico analysis identifies an unannotated antisense long non-coding RNA involved in cancer progression Inoue, S.
 2014
 50 S6 p. 101-
1 p.
 artikel
486 92 Role of ERK nuclear translocation in cisplatin-sensitive and -resistant ovarian cancer cells Dilruba, S.
 2014
 50 S6 p. 34-
1 p.
 artikel
487 455 Role of MDM2 as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) Briest, F.
 2014
 50 S6 p. 149-
1 p.
 artikel
488 2 Safety and early evidence of activity of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors Patnaik, A.
 2014
 50 S6 p. 7-
1 p.
 artikel
489 292 Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle rendering them chemosensitive Yano, S.
 2014
 50 S6 p. 96-
1 p.
 artikel
490 343 Salmonella typhimurium A1-R effectively targets experimental breast cancer brain metastasis Zhang, Y.
 2014
 50 S6 p. 111-
1 p.
 artikel
491 Scientific Programme – Details 2014
 50 S6 p. xx-lxxi
nvt p.
 artikel
492 Scientific Programme – Overview 2014
 50 S6 p. xviii-xix
nvt p.
 artikel
493 471 Screening of Champions predictive TumorGraft platform guides the clinical development of the selective dual BRAF-EGFR inhibitor CEP-32496 Ruggeri, B.
 2014
 50 S6 p. 154-
1 p.
 artikel
494 344 Search for new blood biomarkers for response to antiangiogenic therapy in non-small cell lung cancer patients Rodríguez-Garzotto, A.
 2014
 50 S6 p. 111-
1 p.
 artikel
495 247 Selective inhibitors of nuclear export (SINE) block the expression of DNA damage repair proteins and sensitize cancer cells to DNA damage therapeutic agents Kashyap, T.
 2014
 50 S6 p. 83-
1 p.
 artikel
496 371 Selective targeting of head and neck cancer cells by perturbing reactive oxygen species homeostasis Kwon, M.
 2014
 50 S6 p. 119-
1 p.
 artikel
497 40 Selectivity and mechanism of action studies for Polo Box-targeted, non-ATP based inhibitors of PLK1 Baxter, M.
 2014
 50 S6 p. 18-19
2 p.
 artikel
498 305 Selinexor, a novel selective inhibitor of nuclear export, potentiates the antitumor activity of gemcitabine against pancreatic cancer by nuclear retention of p27 Amit, M.
 2014
 50 S6 p. 100-
1 p.
 artikel
499 337 Sensitisation of HPV+ HNSCC to cytotoxic treatments by targeting the G2/M checkpoint with AZ-1775 to improve survival Osman, A.
 2014
 50 S6 p. 109-
1 p.
 artikel
500 157 Sensitive and specific detection of 1p/19q codeletion in gliomas by next generation sequencing Dubbink, E.
 2014
 50 S6 p. 53-
1 p.
 artikel
501 394 Sensitivity of acute myeloid leukemia cells to a urokinase-activated anthrax lethal toxin (PrAgU2/lf) is dependent on uPAR expression and phospho-MEK1/2 levels Bekdash, A.
 2014
 50 S6 p. 126-
1 p.
 artikel
502 81 Sensitization of triple-negative breast cancer to PI3K inhibition by cotargeting IGF1R de Lint, K.
 2014
 50 S6 p. 31-
1 p.
 artikel
503 278 Sentinel lymph nodes mapping of macrophage targeted mannosyl human serum albumin-indocyanine detected by combined color and near infrared fluorescence imaging system in esophagus Quan, Y.
 2014
 50 S6 p. 92-
1 p.
 artikel
504 426 Serum levels of CCL22 and CCL25 might predict skin rash induction the commonest adverse event by bendamustine in the treatment of malignant lymphoma Terni, Y.
 2014
 50 S6 p. 136-
1 p.
 artikel
505 575 SF3B1 mutations are associated with alternative splicing in ER-positive breast cancer Maguire, S.
 2014
 50 S6 p. 186-
1 p.
 artikel
506 456 SF3B1 mutations induce disease relevant aberrant mRNA splicing in cancer and confer sensitivity to spliceosome inhibition Buonamici, S.
 2014
 50 S6 p. 149-
1 p.
 artikel
507 536 Shifts in microRNA expression pattern can facilitate the cancer cell stemness Halytskiy, V.
 2014
 50 S6 p. 174-
1 p.
 artikel
508 333 Short antisense oligonucleotides antagonize Lin28 and enable pre-let-7 processing and suppression of cell growth in human hepatocarcinoma cells Roos, M.
 2014
 50 S6 p. 108-
1 p.
 artikel
509 273 Significance of serine-167 and cysteine-129 residues in the active site of the immune-suppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1) for the binding of novel inhibitors Tomek, P.
 2014
 50 S6 p. 91-
1 p.
 artikel
510 49 siRNA targeting of mitochondrial thymidine kinase 2 (TK2) sensitizes cancer cells to gemcitabine and increases mitochondrial toxicity Di Cresce, C.
 2014
 50 S6 p. 21-
1 p.
 artikel
511 393 Small modification of ceritinib enhances the activity against ALK Park, C.H.
 2014
 50 S6 p. 126-
1 p.
 artikel
512 100 Small molecules selectively targeting breast cancer cells Sakoff, J.
 2014
 50 S6 p. 36-
1 p.
 artikel
513 155 SNIPER(TACC3) degrades TACC3 protein via the ubiquitin–proteasome pathway and induces apoptosis in cancer cells expressing a large amount of TACC3 Ohoka, N.
 2014
 50 S6 p. 52-53
2 p.
 artikel
514 Societies' Profiles 2014
 50 S6 p. ix-x
nvt p.
 artikel
515 60 Sodium metaarsenite cytotoxic activity is associated with telomere length and many types of arsenic transporters in non-small cell lung cancer Park, Y.M.
 2014
 50 S6 p. 24-25
2 p.
 artikel
516 512 Somatically mutated ABL1 represents an actionable and essential lung cancer survival gene Testoni, E.
 2014
 50 S6 p. 167-
1 p.
 artikel
517 183 Spatio-temporal characterization of tumor growth and invasion Jimenez, A.M.
 2014
 50 S6 p. 60-
1 p.
 artikel
518 372 Specific inhibition of hTERT expression by targeting common promoter mutations which cause quadruplex DNA instability Miller, D.
 2014
 50 S6 p. 120-
1 p.
 artikel
519 84 Src family kinase activation is a compensatory survival mechanism for acquired resistance to EGFR-TKIs in lung cancer cells Ono, M.
 2014
 50 S6 p. 32-
1 p.
 artikel
520 197 Statistical aspects of kinetic analysis of gliomas with FDG-PET Hawe, D.
 2014
 50 S6 p. 64-
1 p.
 artikel
521 593 Strategies to overcome resistance to BET bromodomain inhibitor in KRAS/LKB1 mutant NSCLC Soucheray, M.
 2014
 50 S6 p. 191-
1 p.
 artikel
522 307 Stromal delivery of long Pentraxin-3 impairs FGF/FGFR-dependent tumor growth and metastasis Giacomini, A.
 2014
 50 S6 p. 100-101
2 p.
 artikel
523 407 Structural basis for inhibition of ligand-dependent and -independent ErbB3 activation by KTN3379 Alvarado, D.
 2014
 50 S6 p. 130-
1 p.
 artikel
524 17 Studies on glycoprotein expression differences between MCF-7 and MCF-7-Z Ner-Kluza, J.
 2014
 50 S6 p. 12-
1 p.
 artikel
525 Subject Index 2014
 50 S6 p. 229-239
11 p.
 artikel
526 573 Suppression of c-Myc oncogene and hematological tumor growth by a novel benzazepine BET inhibitor Gelato, K.A.
 2014
 50 S6 p. 185-
1 p.
 artikel
527 36 Suppression of metastasis and improvement of drug distribution by eribulin mesylate Ozawa, Y.
 2014
 50 S6 p. 17-
1 p.
 artikel
528 224 Synergic tumor growth suppression with carbohydrate-restriction diet and natural AMP-dependent protein kinase activators Choi, M.
 2014
 50 S6 p. 76-
1 p.
 artikel
529 349 Synergistic drug combinations that target beta-catenin-driven and MYC-driven cancers Uitdehaag, J.C.M.
 2014
 50 S6 p. 113-
1 p.
 artikel
530 98 Synergistic inhibition of HER2 positive breast cancer by triptolide and lapatinib Chalugun, P.
 2014
 50 S6 p. 36-
1 p.
 artikel
531 513 Synergistic inhibition of ovarian and endometrial cancer cell lines using combined treatment of ARQ 092 and ARQ 087 in vitro and in vivo Yu, Y.
 2014
 50 S6 p. 167-
1 p.
 artikel
532 19 Syngeneic models for developing cancer therapeutics targeting immune system Zhang, L.
 2014
 50 S6 p. 12-
1 p.
 artikel
533 288 Synthetic isomalyngamide A analogs that inhibit breast cancer migration Li, W.
 2014
 50 S6 p. 95-
1 p.
 artikel
534 294 Synthetic lethal screen identifies Aurora A as a selective target in HPV driven cervical cancer Gabrielli, B.
 2014
 50 S6 p. 97-
1 p.
 artikel
535 187 Targeted genomic profiling of penile squamous cell carcinoma using the Oncomine cancer research panel McDaniel, A.S.
 2014
 50 S6 p. 61-
1 p.
 artikel
536 419 Targeted inhibition of casein kinase II (CK2) produces a strong therapeutic effect in pediatric leukemia Dovat, S.
 2014
 50 S6 p. 134-
1 p.
 artikel
537 366 Targeting colorectal and pancreatic cancer stem cells with the LGR5 monoclonal antibody BNC101 Chu, P.
 2014
 50 S6 p. 118-
1 p.
 artikel
538 524 Targeting MET for a differentiation therapy of rhabdomyosarcoma Skrzypek, K.
 2014
 50 S6 p. 170-
1 p.
 artikel
539 404 Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung Cavazzoni, A.
 2014
 50 S6 p. 129-
1 p.
 artikel
540 123 Targeting tryptophan metabolism in human lung cancer Deshane, J.
 2014
 50 S6 p. 43-
1 p.
 artikel
541 442 Targeting urokinase plasminogen activator for radioimmunotherapy using an antagonistic internalizing human antibody LeBeau, A.
 2014
 50 S6 p. 145-
1 p.
 artikel
542 401 TAS-121, a highly potent and mutant-specific EGFR inhibitor, overcomes T790M-acquired resistance with promising antitumor activity through specific inhibition of mutant EGFR signaling Kato, M.
 2014
 50 S6 p. 128-
1 p.
 artikel
543 592 TAS-116, a highly selective inhibitor of heat shock protein 90a/β, inhibits tumor growth in biliary tract cancer mouse models Ohkubo, S.
 2014
 50 S6 p. 191-
1 p.
 artikel
544 515 TAS-115, a potent MET/VEGFR-targeted kinase inhibitor, is a new therapeutic approach for the treatment of bone metastasis of lung cancer Gomori, A.
 2014
 50 S6 p. 167-168
2 p.
 artikel
545 398 TAS-119 a selective inhibitor of Aurora A kinase, potentiates taxane therapy in breast and lung cancer models Nakatsuru, Y.
 2014
 50 S6 p. 127-128
2 p.
 artikel
546 29 TAS-114 is a novel dUTPase/DPD inhibitor, its DPD inhibition reduces capecitabine dosage but does not diminish therapeutic window in human tumor xenografts Yano, W.
 2014
 50 S6 p. 15-
1 p.
 artikel
547 27 TAS-102 treatment results in high trifluridine incorporation into DNA with pyrimidine metabolic pathway markedly up-regulated in cancer Oguchi, K.
 2014
 50 S6 p. 15-
1 p.
 artikel
548 128 T cell-mediated cancer immunotherapy through OX40 agonism Huseni, M.
 2014
 50 S6 p. 45-
1 p.
 artikel
549 541 The abnormal bone remodeling associated with prostate cancer bone metastasis is attenuated by TAS-115, the dual inhibitor for HGF/VEGF signaling Fujita, H.
 2014
 50 S6 p. 176-
1 p.
 artikel
550 505 The anti-ErbB3 antibody, EV20, counteracts vemurafenib resistance in BRAF-mutated colorectal cancer stem cells Sala, G.
 2014
 50 S6 p. 164-165
2 p.
 artikel
551 568 The BET bromodomain inhibitor OTX015 shows synergy with several anticancer agents in preclinical models of mantle cell lymphoma (MCL) and multiple myeloma (MM) Bernasconi, E.
 2014
 50 S6 p. 184-
1 p.
 artikel
552 529 The Cancer Research UK Stratified Medicine Programme: From national screening to national trial Mirabile, I.
 2014
 50 S6 p. 172-
1 p.
 artikel
553 446 The cancer stem cell inhibitors VS-6063 (defactinib) and VS-5584 exhibit synergistic anticancer activity in preclinical models of mesothelioma Xu, Q.
 2014
 50 S6 p. 146-147
2 p.
 artikel
554 240 The combination of Chk-1 and ATR inhibitor synergistically kills cancer cells Sanjiv, K.
 2014
 50 S6 p. 81-
1 p.
 artikel
555 584 The correlation between EMT and cancer stemness in lung adenocarcinoma affects on its prognosis Sowa, T.
 2014
 50 S6 p. 188-
1 p.
 artikel
556 158 The development of a series of orthotopic solid tumour models of prostate, lung and ovarian cancer using optical and X ray imaging Batey, M.
 2014
 50 S6 p. 53-
1 p.
 artikel
557 323 The development of short form of mimic microRNA for lung cancer therapy Ohno, S.
 2014
 50 S6 p. 105-
1 p.
 artikel
558 283 The development of the first selective inhibitors of the UBA5 enzyme to probe for E1 activity in diseased cells da Silva, S.R.
 2014
 50 S6 p. 94-
1 p.
 artikel
559 479 The discovery and development of potent and specific anti-SialylTn antibodies for the treatment of solid tumors Meetze, K.
 2014
 50 S6 p. 156-
1 p.
 artikel
560 287 The discovery and optimization of small molecule antagonists of the WDR5–MLL interaction Al-Awar, R.
 2014
 50 S6 p. 95-
1 p.
 artikel
561 277 The discovery and pre-clinical development of the first clinical stage EZH2-inhibitor, EPZ-6438 (E7438) Kuntz, K.
 2014
 50 S6 p. 92-
1 p.
 artikel
562 252 The DNA damage response gene Schlafen 11 (SLFN11) is a transcriptional target of ETS transcription factors in Ewing's sarcoma and other cancers Pommier, Y.
 2014
 50 S6 p. 84-
1 p.
 artikel
563 50 The effect of esomeprazole, a proton pump inhibitor, on the pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors or lymphomas Zhou, X.
 2014
 50 S6 p. 21-22
2 p.
 artikel
564 336 The effect of food on the pharmacokinetics of the investigational Aurora A kinase (AAK) inhibitor, alisertib (MLN8237), in patients (pts) with advanced solid tumors or lymphomas Zhou, X.
 2014
 50 S6 p. 109-
1 p.
 artikel
565 207 The enhancement of radiotherapy efficacy with docetaxel-titanate nanotubes as a new nanohybrid for localized high risk prostate cancer Mirjolet, C.
 2014
 50 S6 p. 67-
1 p.
 artikel
566 30 The fungal-derived cyclohexadepsipeptide Destruxin E exerts multifaceted anticancer and antiangiogenic activities Dornetshuber-Fleiss, R.
 2014
 50 S6 p. 16-
1 p.
 artikel
567 518 The HSP90 inhibitor, AT13387, overcomes resistance to crizotinib and second generation ALK inhibitors Courtin, A.
 2014
 50 S6 p. 168-
1 p.
 artikel
568 193 The identification of new therapies for ependymoma subgroups Boulos, N.
 2014
 50 S6 p. 63-
1 p.
 artikel
569 38 The indolyl-chalcone CDD-026 induces cancer cell death through targeting of STMN1 and mitotic catastrophe Wegiel, B.
 2014
 50 S6 p. 18-
1 p.
 artikel
570 200 The influence of different cMET and EGFR backgrounds on the cytotoxicity of cMET and EGFR small molecule inhibitors in vitro van der Steen, N.
 2014
 50 S6 p. 65-
1 p.
 artikel
571 585 The investigational HSP90 inhibitor ganetespib displays robust single agent activity in gastric cancer models both as monotherapy and in combination with standard of care therapeutics He, S.
 2014
 50 S6 p. 188-189
2 p.
 artikel
572 269 The NCI-60 as an effective tool for scaffold hopping: A phenotypic systems-based approach to the design of novel chemotherapeutics Wishka, D.G.
 2014
 50 S6 p. 89-90
2 p.
 artikel
573 202 The novel microtubule-destabilizing drug BAL101553 (prodrug of BAL27862) sensitizes a treatment refractory tumor model to ionizing radiation Broggini-Tenzer, A.
 2014
 50 S6 p. 65-66
2 p.
 artikel
574 583 The 8p11 amplicon in luminal breast cancers harbors multiple interacting epigenome modifying oncogenes: implications for epigenome-targeted therapy Ethier, S.
 2014
 50 S6 p. 188-
1 p.
 artikel
575 412 The Pediatric Preclinical Testing Program (PPTP): Analysis of the first 10 years in vivo testing Houghton, P.
 2014
 50 S6 p. 131-132
2 p.
 artikel
576 546 The PI3Kbeta/delta inhibitor AZD8186 combines with the dual mTORC1/2 inhibitor AZD2014 to give comprehensive PI3K pathway inhibition and drive tumour regression in vivo Simon, B.
 2014
 50 S6 p. 177-
1 p.
 artikel
577 312 The prognostic role of mesothelin expression and its association with KRAS mutation in advanced lung adenocarcinoma Thomas, A.
 2014
 50 S6 p. 102-
1 p.
 artikel
578 441 The role of méthylation in metastasis of oral squamous cell carcinoma: understanding the OSCC methylome Clausen, M.
 2014
 50 S6 p. 145-
1 p.
 artikel
579 475 The synergistic anti-proliferative effect of combining the FGFR inhibitor, ARQ 087 with the AKT inhibitor, ARQ 092 in human cancer cell lines and PDX models Marchlik, E.
 2014
 50 S6 p. 155-
1 p.
 artikel
580 103 The use of next generation sequencing (NGS) in the management of metastatic breast cancer (MBC): Defining a model for genomic-driven therapies Austin, L.
 2014
 50 S6 p. 37-
1 p.
 artikel
581 186 The use of Quantitative Textural Analysis imaging biomarkers to predict response to temsirolimus treatment in advanced HCC subjects Korn, R.
 2014
 50 S6 p. 61-
1 p.
 artikel
582 89 Tie-2 regulates the stemness of prostate cancer cells Tang, K.
 2014
 50 S6 p. 33-
1 p.
 artikel
583 521 Tisular expression of the EGFR and N-Glycolyl GM3 Ganglioside as recognized by ior egf/r3 and 14F7 Mabs in triple negative breast cancer Perez, A. Calvo
 2014
 50 S6 p. 169-
1 p.
 artikel
584 542 Tivantinib in combination with gemcitabine shows strong antitumor activity on mesothelioma cell lines and cytoskeletal effects via inhibition of actin Simonelli, M.
 2014
 50 S6 p. 176-
1 p.
 artikel
585 114 Toll-like receptor 5 agonist entolimod as a potential anticancer immunotherapeutic agent Burdelya, L.
 2014
 50 S6 p. 40-
1 p.
 artikel
586 48 Trabectedin and lurbinectedin are effective against leukemic cells derived from patients affected by chronic and juvenile myelomonocytic leukemia Romano, M.
 2014
 50 S6 p. 21-
1 p.
 artikel
587 470 Transcriptional regulation of cancer stem cells marker CD133 by p53 Park, E.K.
 2014
 50 S6 p. 153-154
2 p.
 artikel
588 409 Transcription factor activating protein 2 beta (TFAP2B) mediates neuronal differentiation in neuroblastoma Ikram, F.
 2014
 50 S6 p. 130-131
2 p.
 artikel
589 201 Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer Kim, S.
 2014
 50 S6 p. 65-
1 p.
 artikel
590 182 TRAP1 represents a key mediator of stemness and glycolytic metabolism in colorectal cancer cells Lettini, G.
 2014
 50 S6 p. 60-
1 p.
 artikel
591 Travel Grants 2014
 50 S6 p. xvii-
1 p.
 artikel
592 484 Treatment of advanced solid tumors with golvatinib (E7050) in combination with lenvatinib (E7080) Kwak, E.L.
 2014
 50 S6 p. 158-
1 p.
 artikel
593 185 Treatment of patient-derived NSCLC xenograft preclinical models using image-guided small animal irradiation Papadopoulou, N.
 2014
 50 S6 p. 60-61
2 p.
 artikel
594 500 Triple blockade with LEE011, everolimus, and exemestane in women with ER+/HER2− advanced/metastatic breast cancer: results from a Phase Ib clinical trial Bardia, A.
 2014
 50 S6 p. 163-
1 p.
 artikel
595 90 Tumor infiltrating leukocyte subpopulations as a biomarker of response and resistance to targeted therapy in patients with BRAF mutation-positive metastatic melanoma Kelley, M.C.
 2014
 50 S6 p. 33-34
2 p.
 artikel
596 136 Tumor-infiltrating lymphocytes (TILs) following intratumoral administration of ONCOS-102 are associated with prolonged overall survival in last line solid tumor patients Pesonen, S.
 2014
 50 S6 p. 47-
1 p.
 artikel
597 360 Tumor suppressive microRNA-192 as a prognostic factor for recurrence of surgically resected non-small cell lung cancer Hong, J.H.
 2014
 50 S6 p. 116-
1 p.
 artikel
598 77 Tumor suppressive roles of miR-221 and miR-222 in lung cancer Sato, M.
 2014
 50 S6 p. 30-
1 p.
 artikel
599 535 Tumor targeting and tissue distribution of solitomab (AMG 110; anti-EpCAM BiTE®) in human EpCAM-positive tumor bearing mice Warnders, F.J.
 2014
 50 S6 p. 174-
1 p.
 artikel
600 376 Tumor-targeting Salmonella typhimurium A1-R enhances gemcitabine–bevacizumab efficacy on a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model Hiroshima, Y.
 2014
 50 S6 p. 121-
1 p.
 artikel
601 467 Two in one – Delivery of apoptotic signal into cancer cells by new class of TRAIL derived, fusion protein Pawlak, S.D.
 2014
 50 S6 p. 152-153
2 p.
 artikel
602 348 Two NSCLC-PDXs with different EGFR exon 20-insertions respond differently to different TKIs Li, H.
 2014
 50 S6 p. 112-
1 p.
 artikel
603 299 Tyk2-src dependence of kidney cancer Krishnan, B.
 2014
 50 S6 p. 98-
1 p.
 artikel
604 352 UNC2025, a novel small molecule MerTK and Flt3 tyrosine kinase inhibitor, has therapeutic activity and promotes sensitivity to chemotherapy in animal models of acute leukemia Graham, D.
 2014
 50 S6 p. 114-
1 p.
 artikel
605 503 UNC2025: A small molecule inhibitor of merTK with efficacy in mouse melanoma models Earp, S.
 2014
 50 S6 p. 164-
1 p.
 artikel
606 215 Updated clinical and preliminary correlative results of ARIEL2, a Phase 2 study to identify ovarian cancer patients likely to respond to rucaparib Swisher, E.
 2014
 50 S6 p. 73-
1 p.
 artikel
607 248 Use of ATR inhibitor in combination with topoisomerase I inhibitor kills cancer cells by disabling DNA replication initiation and fork elongation Jossé, R.
 2014
 50 S6 p. 83-
1 p.
 artikel
608 392 Using modelling & simulation to integrate mouse PK–PD-efficacy with preliminary human PK data to inform the Phase II doses and schedule for the experimental c-Met inhibitor AZD6094 (Volitinib) Jones, R.
 2014
 50 S6 p. 125-126
2 p.
 artikel
609 301 Using PK/PD/efficacy modeling to predict potential of AZD9291 to target brain metastases from advanced NSCLC with EGFR sensitizing mutations (EGFRm+) Yates, J.
 2014
 50 S6 p. 99-
1 p.
 artikel
610 97 Utilization of low passage adenoid cystic carcinoma PDX models to identify novel combination therapies Wick, M.J.
 2014
 50 S6 p. 35-36
2 p.
 artikel
611 177 Validation of 3D primary organoid cultures of colorectal carcinoma as discovery and validation platform for personalized cancer therapy Halonen, P.
 2014
 50 S6 p. 59-
1 p.
 artikel
612 520 Validation of Nanostring for FGFR1 gene expression analysis in squamous non-small cell lung cancer (sqNSCLC) tissue Rooney, C.
 2014
 50 S6 p. 169-
1 p.
 artikel
613 264 Vasculogenic mimicry in small cell lung cancer Trapani, F.
 2014
 50 S6 p. 88-
1 p.
 artikel
614 540 Vemurafenib alters glucose utilization in BRAF-driven human melanoma cells Miniotis, M. Falck
 2014
 50 S6 p. 175-176
2 p.
 artikel
615 13 Whole exome sequence analysis of canine transitional cell carcinoma of the bladder Duval, D.L.
 2014
 50 S6 p. 11-
1 p.
 artikel
616 236 Whole genomic assay on endoscopic ultrasound-guided fine needle aspiration samples of unresectable pancreatic cancer Ha, J.M.
 2014
 50 S6 p. 79-
1 p.
 artikel
617 85 Wnt secretion is required to maintain Wnt activity in colon cancer Voloshanenko, O.
 2014
 50 S6 p. 32-
1 p.
 artikel
618 560 ZEN3365 is a novel BET bromodomain inhibitor for the treatment of hematologic malignancies and solid tumors McLure, K.G.
 2014
 50 S6 p. 181-
1 p.
 artikel
619 131 Zfra activates novel Hyal2+ CD3– CD19– memory spleen cells to block cancer growth, stemness, and metastasis in vivo Chang, N.
 2014
 50 S6 p. 46-
1 p.
 artikel
                             619 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland